NCT Number:  
Document Date: A Multicenter, Open-label Trial to Evaluate the Safety and 
Tolerability of Brexpiprazole in the Treatment of Adult 
Subjects With Borderline Personality Disorder
 [STUDY_ID_REMOVED]
Protocol Amendment Version 1: 01 July 2020Official Title:  
Otsuka Pharmaceutical Development & Commercialization, Inc. 
Investigational Medicinal Product 
Brexpiprazole (OPC-34712) 
REVISED CLINICAL PROTOCOL 
A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole 
in the Treatment of Adult Subjects With Borderline Personality Disorder 
Open-label Trial of Brexpiprazole in the Tr eatment of Borderline Personality Disorder 
Protocol No. 331-201-00195 
IND No. 141091 
EudraCT No. 2019-002897-30 
CONFIDENTIAL  PROPRIETARY INFORMATION 
Clinical Development Phase: 2/3 Sponsor: Otsuka Pharmaceutical 
Development & Commercialization, Inc. 2440 Research Boulevard Rockville, Maryland 20850, United States 
Immediately Reportable Event Syneos  Health Pharmacovigilance & Drug 
Safety 
Amendment 1 Approval: 01 Jul 2020 
Original Approval: 21 Aug 2019 CCI
Protocol 331-201-00195  
2 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020  Trial Conduct for COVID -19 
All procedures and assessments in this protocol are to be followed to the fullest 
extent possible. The sponsor, in coordination with the site, investigator(s), and medical monitor, will continuously monitor and evaluate the benef its and risks to 
subject participation in the clinical trial as it relates to COVID -19. If any 
protocol- specified activities were not able to be performed, or cannot be performed 
due to COVID- 19 considerations, refer to the COVID -19 Addendum for the 
approp riate measures to be followed. Appropriate measures may include replacing 
in-person visits with virtual visits (phone or video) as deemed necessary by the 
investigator to ensure subject safety and maintain protocol requirements.  
Protocol 331-201-00195  
3 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020  Table of Contents  
Trial Conduct for COVID- 19 ....................................................................... 2
Table of Contents  ........................................................................................... 3
List of In-text Tables  ..................................................................................... 8
List of In-text Figures  .................................................................................... 9
1 Protocol Summary  .............................................................................. 10
1.1 Synopsis.............................................................................................................10  
1.2 Schema  ..............................................................................................................16  
1.3 Schedule of Assess ments ...................................................................................17  
2 Introduction  ........................................................................................ 21
2.1 Trial Rationale  ...................................................................................................22  
2.2 Background .......................................................................................................22  
2.3 Known and Potential Risks and Benefits ..........................................................23  
3 Objectives and Endpoints  .................................................................. 24
4 Trial Design  ......................................................................................... 25
4.1 Type/Design of Trial .........................................................................................25  
4.2 Scientific Rationale for Trial Design .................................................................27  
4.3 Dosing Rationale ...............................................................................................27  
4.4 End of Trial Definition  ......................................................................................27  
4.5 Definition of Completed Subjects .....................................................................28  
5 Trial Population  .................................................................................. 28
5.1 Subject Selection and Numbering .....................................................................28  
5.2 Eligibility Criteria ..............................................................................................28  
5.2.1 Inclusion Criteria  ............................................................................................29  
5.2.2 Exclusion Criteria  ...........................................................................................29  
5.3 Lifestyle Considerations ....................................................................................31  
5.3.1 Meals and Dietary Restrictions  .......................................................................31  
5.3.2 Caffeine, Alcohol, and Tobacco .....................................................................31  
5.3.3 Activity  ...........................................................................................................32  
5.4 Screen Failures  ..................................................................................................32  
6 Trial Treatments  ................................................................................. 32
Protocol 331-201-00195  
4 
Confidential - Proprietary Information   Amendment 1 Approval: 01 Jul 2020  6.1 Trial Treatments Administered  .........................................................................32  
6.1.1 Medical Devices  .............................................................................................33  
6.2 Management of Investigational Medicinal Product ..........................................33  
6.2.1 Packaging and Labeling ..................................................................................33  
6.2.2 Storage ............................................................................................................33  
6.2.3 Accountability  .................................................................................................34  
6.2.4 Returns and Destruction .................................................................................34  
6.2.5 Reporting of Product Quality Complaints ......................................................34  
6.2.5.1 Eliciting and Reporting Product Quality Complaints .................................35  
6.2.5.2 Information Required for Reporting Purposes ............................................35  
6.2.5.3 Return Process  .............................................................................................35  
6.2.5.4 Assessment/Evaluation  ...............................................................................35  
6.3 Measures to Minimize/Avoid Bias  ....................................................................35  
6.4 Subject Compliance ...........................................................................................36  
6.5 Concomitant Medications or Therapies ............................................................36  
6.5.1 Prohibited Medications ...................................................................................36  
6.5.2 Benzodiazepine Use During the Trial  .............................................................38  
6.5.3 Permitted Medications or Therapies  ...............................................................38  
6.5.4 Rescue Medications  ........................................................................................39  
6.6 Intervention after the End of the Trial ...............................................................39  
7 Stopping Rules, Withdrawal Criteria, and Procedures  .................. 39 
7.1 Entire Trial or Treatment  ...................................................................................39  
7.2 Individual Site ...................................................................................................39  
7.3 Individual Subject Discontinuation  ...................................................................39  
7.3.1 Treatment Interruption  ....................................................................................39  
7.3.2 Treatment Discontinuation  .............................................................................40  
7.3.3 Documenting Reasons for Treatment Interruption or Discontinuation ..........40  
7.3.4 Withdrawal of Consent ...................................................................................41  
7.3.5 Procedures to Encourage Continued Trial Participation ................................42  
7.4 Definition of Subjects Lost to Follow-up ..........................................................42  
8 Trial Procedures  ................................................................................. 42 
8.1 Efficacy Assessments  ........................................................................................43  
Protocol 331-201-00195 
5 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020   
 
 44 
 44 
 44 
8.2 Pharmacokinetic  Assessments ...........................................................................44  
8.3 Pharmacodynamic Assessments ........................................................................44  
8.4 Pharmacogenomic Assessments ........................................................................44  
8.5 Biomarker Assessments ....................................................................................45  
8.6 Future Biospecimen Research Samples ............................................................45  
8.7 Safety Assessments ...........................................................................................45  
8.7.1 Clinical Laboratory Assessments ...................................................................45  
8.7.2 Physical Examination .....................................................................................46  
8.7.3 Vital Signs ......................................................................................................47  
8.7.4 Electrocardiogram ...........................................................................................47  
8.7.5 Suicidality Monitoring - Columbia -Suicide Severity Rating Scale ................48  
8.7.6 Other Safety Variables ....................................................................................48  
8.7.6.1 Simpson Angus Scale ..................................................................................49  
8.7.6.2 Abnormal Involuntary Movement Scale .....................................................49  
8.7.6.3 Barnes Akathisia Rating Scale ....................................................................50  
8.8 Adverse Events ..................................................................................................50  
8.8.1 Definitions ......................................................................................................50  
8.8.2 Eliciting and Reporti ng Adverse Events .........................................................52  
8.8.3 Immediately Reportable Events ......................................................................53  
8.8.4 Medical Device Incidents (Including Malfunctions) ......................................53  
8.8.5 Adverse Events of Special Interest .................................................................53  
8.8.6 Potential Serious Hepatotoxicity ....................................................................53  
8.8.7 Procedure for Breaking the Blind ...................................................................53  
8.8.8 Follow-up of Adverse Events .........................................................................53  
8.8.8.1 Follow-up of Nonserious Adverse Events ..................................................53  
8.8.8.2 Follow-up of Immediately Reportable Events ............................................54  
8.8.8.3 Follow-up and Reporting of I mmediately Reportable Events 
Occurring After Last Scheduled Contact ....................................................54  CCI
CCI
CCI
CCI
Protocol 331-201-00195 
6 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 8.9 Treatment of Overdose ......................................................................................55  
8.10 Subject Assessment Recording .........................................................................55  
 55 
 55 
 55 
 55 
8.11 Other Assessments ............................................................................................55  
9 Statistical Considerations .................................................................. 56  
9.1 Sample Size .......................................................................................................56  
9.2 Datasets for Analysis .........................................................................................56  
9.3 Handling of Missing Data for Primary  and Secondary Endpoint Analysis ......56  
9.4 Statistical Analyses............................................................................................56  
 56 
9.4.2 Safety Analysis ...............................................................................................56  
9.4.2.1 Adverse Events............................................................................................57  
9.4.2.2 Clinical Laboratory Data .............................................................................57  
9.4.2.3 Physical Examination and Vital Signs Data................................................57  
9.4.2.4 Electrocardiogram Data ..............................................................................57  
9.4.2.5 Other Safety Data ........................................................................................58  
9.4.3 Other Analyses ................................................................................................58  
9.4.3.1 Analysis of Demographic and Baseline Characteristics .............................58  
9.4.3.2 Pharmacokinetic Analysis ...........................................................................58  
9.4.3.3 Pharmacodynamic Analysis ........................................................................58  
9.4.3.4 Pharmacokinetic/Pharm acodynamic Analysis ............................................58  
9.4.3.5 Pharmacogenomic Analysis ........................................................................59  
 59  
9.5 Interim Analysis and Adaptive Design .............................................................59  
9.5.1 Data Monitoring Committee ...........................................................................59  
10 Supporting Documentation and Operational Considerations ....... 60  
10.1 Appendix 1: Regulatory, Ethical, and Trial Oversight Considerations .............60  
10.1.1 Ethics and Responsibility ...............................................................................60  
10.1.2 Informed Consent ...........................................................................................60  CCICCI
CCI
CCI
CCI
CCI
Protocol 331-201-00195  
7 
Confidential - Proprietary Information   Amendment 1 Approval: 01 Jul 2020  10.1.3 Confidentiality  ................................................................................................61  
10.1.4 Quality Control and Quality Assurance ..........................................................62  
10.1.4.1 Monitoring ..................................................................................................62  
10.1.4.2 Auditing ......................................................................................................62  
10.1.5 Protocol Deviations ........................................................................................62  
10.1.6 Records Management  .....................................................................................63  
10.1.6.1 Source Documents ......................................................................................63  
10.1.6.2 Data Collection ............................................................................................63  
10.1.6.3 File Management at the Trial Site  ...............................................................64  
10.1.6.4 Records Retention at the Trial Site  .............................................................65  
10.1.6.5 Publication Authorship Requirements ........................................................65  
10.2 Appendix 2: Clinical Laboratory Tests .............................................................67  
10.3 Appendix 3: Contraceptive Guidance and Collection of Pregnancy 
Inform ation  ........................................................................................................68  
10.4 Appendix 4: Abbreviations ...............................................................................70  
10.5 Appendix 5: Criteria for Identifying Laboratory Values of Potential 
Clinical Relevance  .............................................................................................72  
10.6 Appendix 6: Criteria for Identifying Vital Signs of Potential Clinical 
Relevance  ..........................................................................................................73  
10.7 Appendix 7: Criteria for Identifying ECG Measurements of Potential 
Clinical Relevance  .............................................................................................74  
10.8 Appendix 8: Protocol Amendments  ..................................................................75  
10.8.1 Protocol Amendment(s)/Administrative Change(s) .......................................76  
10.8.1.1 Protocol Amendment 1 ...............................................................................76  
11 R eferences  ............................................................................................ 78 
 
Protocol 331-201-00195  
8 
Confidential - Proprietary Information   Amendment 1 Approval: 01 Jul 2020  List of In -text Tables  
Table 1.3-1 Schedule of Assessments  .............................................................. 17  
Table 3 -1 Trial Objectives and Endpoints ..................................................... 24  
Table 6.1-1 Dosing Schedule ........................................................................... 33  
Table 6.5.1-1 List of Medications Prohibited During the Trial........................... 37  
Table 10.2-1 Clinical Laboratory Assessments  .................................................. 67  
 
 
Protocol 331-201-00195  
9 
Confidential - Proprietary Information   Amendment 1 Approval: 01 Jul 2020  List of In -text Figures  
Figure 1.2-1 Trial Design Schematic  ................................................................. 16  
  
Protocol 331-201-00195  
10 
Confidential - Proprietary Information   Amendment 1 Approval: 01 Jul 2020  1 Protocol Summary 
1.1 Synopsis  
Name of Sponsor:  Otsuka Pharmaceutical Development & Commercialization, Inc.  
Name of Investigational Medicinal Product: Brexpiprazole (OPC -34712) 
Protocol No.:  331-201-00195 
IND No.:  141091  
EudraCT No. : 2019-002897-30 
Protocol Title : A Multicenter, Open- label Trial to Evaluate the Safety and Tolerability of 
Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder 
Protocol Lay Person Short Title : Open -label Trial of Brexpiprazole in the Treatment of 
Borderl ine Personality Disorder   
Clinical Phase/Trial Type:  Phase 2/ 3 / Therapeutic use 
Treatment/Indication:  For the treatment of b orderline personality disorder (BPD) 
Objectives and Endpoints:  
Objectives  Endpoints  
Primary Safety: To evaluate the 
safety and tolerability of 
brexpiprazole for the treatment of subjects with a diagnosis of BPD.
 
 Primary Safety: Frequency and severity of AEs.  
 
Secondary Safety:  
• Changes in: ECGs, vital signs, clinical 
laboratory tests including prolactin, changes in body weight, and physical examinations; 
• EPS: SAS, AIMS, and BARS;  
• Suicidal ideation and behavior will be assessed using the C- SSRS.  
Protocol 331-201-00195 
11 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 Objectives Endpoints 
AE = adverse event; AIMS = Abnormal Involuntary Movement Scale; BARS = Barnes Akathisia Rating 
Scale;   
; 
C-SSRS = Columbia-Suicide Severity Rating Scale;  ECG = electrocardiogram;  EPS = extrapyramidal 
symptom; ET = early termination; ; 
; ; 
SAS = Simpson Angus Scale;  Schedule;  
Note: The assessments from the last  scheduled treatment visit of th e previous double-blind trial will 
serve as the baseline measures for Trial 331-201-00195.  
 
Trial Design:  
This will be a 12-week, multicenter, open-label trial designed to evaluate the safety and 
tolerability of brexpi prazole treatment in adult subject s diagnosed with BPD. Subjects 
will receive 2 to 3 mg/day brexpiprazole. 
Enrollment into the trial will be drawn from eligible subjects who completed the last visit 
of the previous double-blind, brexpiprazole BPD trials (and took the investigational 
medicinal product [IMP] through the last sc heduled treatment visit) and, in the 
investigator’s judgment, could potentially be nefit from treatment with brexpiprazole for 
BPD. CCICCI
CCI CCI
CCICCICCICCI
Protocol 331-201-00195  
12 
Confidential - Proprietary Information   Amendment 1 Approval: 01 Jul 2020  Subjects will be screened for eligibility at the last scheduled treatment visit of the 
previous double- blind trial. Subjects will sign a separate informed consent form (ICF) at 
the last  scheduled treatment visit of the previous double- blind trial for participation in 
Trial  331-201-00195 before any procedures specific to the open- label trial are  performed. 
The assessments from the last scheduled treatment visit of the previous double- blind trial 
will serve as the baseline measures for Trial 331 -201-00195 for any assessment that is not 
new ( unique) to the open-label trial. Medical history will be updated, if necessary. 
Informed consent cannot be obtained after the last scheduled treatment visit of the previous double-blind trial without all screening/baseline assessments being repeated. If a 
subject  is unable to rollover immediately, up to 3 days may be permitted between the end 
of the double-blind trial and the start of IMP in the open-label extension trial; however, this must be discussed with the medical monitor (Note: assessments from the last scheduled treatment visit in the previous double-blind trial that are going to be used as 
the baseline measures for Trial 331 -201-00195 will not need to be repeated if the subject 
enters Trial  331-201-00195 within 3 days). 
Eligible subjects will receive up to 12 weeks of daily treatment with open -label 
brexpiprazole. A safety follow-up telephone contact or clinic visit will occur 21 (± 3) days after the last dose of brexpiprazole. 
Trial Population: 
The trial population will consist of eligible male  and female subjects diagnosed with BPD  
and who, in the investigator’s judgment, could potentially benefit from treatment with 
brexpiprazole for BPD according to the following criteria: 
• Subjects who participated in a double- blind brexpiprazole BPD trial will be eligible 
for Trial 331 -201-00195 if they have completed the last scheduled treatment visit of  
the previous double- blind trial and did not terminate early.  
• Subjects must qualify for Trial 331-201-00195 at the last scheduled treatment visit of 
the previous double-blind trial and must be able to continue treatment  without 
interruption between the double-blind and open- label trials  (if a subject is unable to 
rollover immediately, up to 3 days may be permitted between the end of the 
double-blind trial and the start of IMP in the open-label extension trial; however, this 
must be discussed with the medical monitor) .  
 
Protocol 331-201-00195  
13 
Confidential - Proprietary Information   Amendment 1 Approval: 01 Jul 2020  Key Inclusion/Exclusion Criteria:  
Male or female outpatients , ages 18 to 65 years (at the time of informed consent of the 
previous double-blind trial), with a BPD diagnosis who completed the last treatment visit 
of the previous double-blind brexpiprazole BPD trial and who, in the opinion of the investig ator, could potentially benefit from administration of brexpiprazole for the 
treatment of BPD. Eligible subjects must not have a major protocol deviation during the 
course of their particip ation in the previous double-blind brexpiprazole BPD trial  (if the 
major protocol deviation is due to the coronavirus disease of 2019 [COVID-19], 
eligibility for the subject to continue can be discussed with medical monitor).  
Trial Site(s):   
This trial will be conducted at multiple sites globally . 
Investigational Medicinal Product(s), Dose, Dosage R egimen, Treatment Duration, 
Formulation, Mode of Administration: 
All subjects will receive a starting dose of 1  mg/day  at the screening/baseline visit , 
followed by an increase to 2 mg/day at the end of Week  1. Subjects may increase their 
dose to 3 mg/day at the investigator’s discretion on or after the Week 2 visit, depending 
on treatment response and tolerability. Subjects taking 3 mg/day may down- titrate to 
2 mg/day based on tolerability at any time during the course of the trial. Subjects unable 
to tolerate 2 mg/day will be discontinued from the trial. Dose adjustments to 
brexpiprazole must be made in increments of 1 mg/day. Dose decreases for brexpiprazole can occur at unscheduled visits and dose increases for brexpiprazole can only occur at 
scheduled visits. 
As applicable, dose changes of background antidepressant therapy (ADT) can be 
modified to achieve optimum efficacy and tolerability. Dose adjustments of ADT should not occur at the same visit as a dose adjustment of brexpiprazole and a recommended 
minimum of 5 days should occur between any dose adjustments of brexpiprazole or ADT 
at any point during the trial. 
Dosing Schedule  
IMP  Screening /Baseline  - Week 1  Week 1 - Week 2  Week 2 - Week 12a 
Brexpiprazole  1 mg/day  2 mg/day  2 or 3 mg/dayb 
aDown titration can occur at any time due to tolerability after Week 2. The minimum dose allowed is 
2 mg/day.  
bOption to titrate to 2 or 3 mg/day (ie, 2 mg, or 3 mg) based on clinical response and tolerability; 
changes must occur in 1 mg/day increments.  
 
Protocol 331-201-00195 
14 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 Trial Assessments: 
 
 
 
 
 
 
 
Assessments for Pharmacokine tics/Pharmacodyn amics: None. 
Assessments for Safety: Adverse event (AE) re porting, clinical laboratory tests (including 
prolactin and glycosylated he moglobin [HbA1c]), electrocard iogram (ECG), vital signs, 
physical examination, Simpson Angus Scal e (SAS), Abnormal Involuntary Movement 
Scale (AIMS), Barnes Akathisia Rating Scal e (BARS), and Columbia -Suicide Severity 
Rating Scale (C-SSRS). 
Screening/Other: Medical, psychiatric, and medication history; urine drug and blood 
alcohol screening; and urine pregnancy test. 
Data Monitoring Committee: None.  
Statistical Methods: 
The sample size is not based on statistical power considerations but on the number of 
subjects rolling over from the lead-in trials . The trial population will be derived from 
eligible subjects who completed the previous  double-blind brexpiprazole BPD trials. The 
number of eligible subjects will be limited by the number of subjects enrolled into the 
double-blind trials.  
The primary safety analysis is the frequenc y and severity of AEs in the open-label 
treatment phase. All AEs will be coded by system organ class and the Medical Dictionary 
for Regulatory Activities preferred term. The incidence of the following events will be 
summarized by the prior treatment group: 
1) Treatment-emergent adverse events (TEAEs) 
2) TEAEs by severity, 
3) TEAEs potentially causally related to the IMP, 
4) TEAEs with an outcome of death, 
5) Serious TEAEs, 
6) TEAEs leading to discontinuation of the IMP, 
7) Adverse events of special interest (AESI). CCI
Protocol 331-201-00195  
15 
Confidential - Proprietary Information   Amendment 1 Approval: 01 Jul 2020   
A TEAE is defined as an AE that starts after the first dose of IMP or an AE that is 
reported at baseline and increases in intensity or becomes serious or IMP-related or 
results in death, discontinuation, interruption or reduction of IMP. Information about new onset or exacerbation of “Pathological Gambling and Other Compulsive Behaviors” will be collected and analyzed as an AE of special interest.  
Complete details of the planned statistical analysis will be presented in the statistical 
analysis plan. 
Trial Duration: Each subject in this trial is expected to participate in the following periods of the trial 
(approximate durations listed), for approximately 15 weeks: 
• Eligibility screening period (1 day ) (If a subject is unable to rollover immediately, up 
to 3 days may be permitted between the end of the double-blind trial and the start of 
IMP in the open-label extension trial; however, this must be discussed with the medical monitor.)  
• Treatment period (12 weeks)  
• Post- treatment follow -up period (21 ± 3 day s) 
 Eligible subjects from the previous double- blind trials will be eligible to roll over into 
this open- label extension trial. Overall, the trial duration from first ICF signed to the final 
subject assessment is expected to be several years . 
Protocol 331- 201-00195  
16 
Confidential - Proprietary Information    Amendment 1 Approval: 01 Jul 2020  1.2 Schema  
 
 
 
   
 
   
 
 
 
aThe l ast visit of the previous double -blind BPD trial will serve as the baseline measures for Trial 331 -201-00195. If a subject is unable to 
rollover immediately, up to 3 days may be permitted between the end of the double -blind trial and the  start of IMP in the open -label extension trial; 
however, this must be discussed with the medical monitor.  
bTelephone contact or clinic visit.  
cTelephone contact will be made at Weeks 1, 6, and 10 to assess AEs and concomitant therapy.  
 
Figure 1.2-1 Trial Design Schematic  
  
Open 
- 
label  
Brexpiprazole  
(2 mg/day to 3 mg/day  
) 
Treatment  
Phase  
 Screening/  
Baseline  
a 
Visits at end of Weeks 2, 4, 8, and 12 (unscheduled visits as necessary for IMP dose decreases)  
Safety  
Follow  
- 
Up 
Last 
visit 
of 
the 
previous  
double  
- 
blind 
BPD 
trial 
b 
Week 1c 
 Week 2  
 Week 4 
 Week 8 
Eligible subjects who 
completed a double- blind BPD 
trial and who, in the opinion of 
the investigator, could 
potentially benefit from the 
administration of brexpiprazole 
for the treatment of BPD  
Week 6c 
 Week 10c 
 Week 12/ET  Week 15 
(21 [± 3] days 
after last dose)  
Protocol 331-201-00195 
17 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 1.3 Schedule of Assessments 
Table 1.3-1 Schedule of Assessments 
Assessment  Visit  
Treatment Period  
Screening/ 
Baselinea,b Week 1c,d Week 2c Week 4c Week 6 c,d Week 8c Week 10c,d Week 12 
or ETc,e Post-
treatment 
Follow-upf 
 ± 3 days  21 ± 3 days  
ENTRANCE CRITERIA 
Informed consentg X         
Inclusion and exclusion criteriag X         
Confirmation of eligibilityg X         
Medical historyg X         
Psychiatric history, including BPD 
historyg X     
  
  
SAFETY 
Physical examinationi X       X  
Vital signsj X  X X  X  X  CCI
Protocol 331-201-00195  
18 
Confidential - Proprietary Information   Amendment 1 Approval: 01 Jul 2020  Table 1.3-1 Schedule of Assessments  
Assessment  Visit  
Treatment Period   
Screening/ 
Baselinea,b Week 1c,d Week 2c Week 4c Week 6 c,d Week 8c Week 10c,d Week 12 
or ETc,e Post-
treatment 
Follow -upf 
 ± 3 days  21 ± 3 days  
Clinical laboratory tests 
(hematology [including HbA1c ], 
serum chemistry  [including 
prolactin] , urinalysis)  Xk     
  
Xl  
ECGm X       X  
Urine pregnancy test (FOCBP 
only)n X   X  
X  
X  
Urine drug screen and blood 
alcohol testo X     
  
X  
C-SSRSp X  X X  X  X  
EPS scales (SAS, AIMS, BARS)  X   X  X  X  
Adverse eventsq X X X X X X X X X 
Concomitant therapyr X X X X X X X X X 
OTHER PROCEDURES  
IMP dispensingg X  X X  X    
IMP accountability    X X  X  X  
Dose adjustments   X X  X  X  
Schedule optional telephone 
contact/other communicationt   X X X X X   
FOCBP = female of childbearing potential.  
aScreening for Trial 331- 201-00195 occurs on the same day as baseline but prior to any procedures specific to the open- label trial. Informed consent for 
Trial  331-201-00195 should be signed at the start of the last double -blind treatment visit. The screenin g/baseline for Trial 331- 201-00195 will be the same 
day as the last visit of the previous double -blind trial.  
Protocol 331-201-00195  
19 
Confidential - Proprietary Information   Amendment 1 Approval: 01 Jul 2020  bThe assessments from the last scheduled treatment visit of the previous double -blind trial will serve as the baseline measures for Trial 331 -201-00195 for any 
assessment that is not new ( unique ) to the open- label trial.  If a subject is unable to rollover immediately, up to 3 days may be permitted between the end of 
the double -blind trial and the start of IMP in the open- label extension trial; howev er, this must be discussed with the medical monitor (Note: assessments 
from the last scheduled treatment visit in the previous double -blind trial that are going to be used as the baseline measures for Trial 331- 201-00195 will not 
need to be repeated if the subject enters Trial 331 -201-00195 within 3 days).  
cWeek designations correspond to the end of the week (eg, Week 4 visit occurs at the end of week 4 of the trial).  
dTelephone contact will be made at Weeks 1, 6, and 10 to assess AEs and concomitant therap y. 
eIf a subject discontinues early, every effort should be made to complete the Week 12/ET evaluations as soon as possible and, whenever possible , prior to 
starting any new medication or treatment.  
fTelephone contact or clinic visit (investigator’s discre tion) for evaluation of safety, 21 days after the last dose.  
gNew (unique) assessments for Trial 331 -201-00195 include informed consent, inclusion/exclusion criteria, confirmation of eligibility, changes in medical 
and psychiatric history, and dispensing of IMP.  
hAny post -screening/baseline visit should refer to screening/baseline when assessing change.  
iTo include measurement of waist circumference.  
jVital sign measurements include body weight, body temperature, systolic blood pressure, diastolic blood pressure, and heart rate. Blood pressure and heart 
rate will be measured in the following order: supine and standing after the subject has been in each position for at least 3 minutes. Vital signs scheduled for 
the same visit as blood samples are to be completed before blood is drawn.  
kSubjects should be fasting for a minimum of 8 hours prior to blood draws for screening/baseline laboratory assessments, if at all possible. If fasting blood 
samples are not feasible at screening /baseline , nonfasting blood samples may be obtained initially for determining eligibility for the trial and need to be 
repeated at the next visit at the discretion of the investigator.  
lBlood samples for clinical laboratory tests should be drawn after a minimum 8 -hour fast at Week  12/ET, if possible. Vital sign and ECG assessments should 
be completed before any blood samples are collected.  
mStandard ECGs will be performed after the subject has been supine and at rest for ≥  5 minutes prior to the ECG. Subjects will be enrolled in 
Trial 331-201-00195 based on the screening/baseline ECG results from the trial site. Any ECGs scheduled for the same visit as blood samples  are to be 
completed before blood is drawn.  
nAll positive urine pregnancy test results must be confirmed by a serum test. Pregnancy tests can be performed at any point during the trial if pregnancy is 
suspected.  
oA urine drug screen and a blood alcohol test are required at the designated times, but either or both can be conducted at any time during the trial at the 
discre tion of the investigator. See the exclusion criteria for exclusions based on urine drug screen and blood alcohol tests at screening /baseline . 
pThe “Since Last Visit” C -SSRS form will be completed at all visits for all subjects.  
Protocol 331-201-00195  
20 
Confidential - Proprietary Information   Amendment 1 Approval: 01 Jul 2020  qAdverse events recording will begin with the signing of the ICF for Trial 331 -201-00195 and through the last scheduled trial visit ( immediately reportable 
events  will be collected through the last trial contact).  
rAll prescription and non- prescription therapy (pharmacological or other therapy) taken during the trial will be recorded. Details of prohibited therapies are 
provided in Section  6.5.1. 
sSee Section  6.1 for dose adjustment details.  
tSche dule an optional telephone call or other form of communication with the subject approximately 1 week (±  2 days) after the visit (eg, at Weeks 3, 5, 7, 9, and 
11) to check on status.  
 
Protocol 331-201-00195  
21 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  2 Introduction 
Borderline personality disorder (BPD) is a mental disorder consisting of a pervasive 
pattern of instability in regulation of emotions, impulse control, interpersonal 
relationships, and self- image.1,2 Patients with BPD are p rone to self -harm (including 
suicide), other dangerous behaviors, substance abuse, depression and eating disorders.3 
The prevalence of B PD has been reported to be as high as 5.9% in the general 
population4 but represents 15% to 29% of patients in psychiatric clinics and hospitals.5,6 
Because the personality of children and adolescents is developing, the features of BPD do not become recognizable until late adolescence or early adulthood.
7,8 There is a high 
comorbidity of BPD with other psychiatric disorders (84.5%), including anxiety, mood, impulse control, and substance disorders.
9  
Brexpiprazole (REXULTI®) is a novel atypical antipsychotic that is a 
serotonin-dopamine activity modulator and is indicated in the United States (US) as 
monotherapy for the treatment of schizophrenia in adult patients (2 - 4 mg/day) and as an 
adjunctive therapy to antidepressants for the treatment of major depressive disorder 
(MDD; 2  - 3 mg /day).10  
While the precise mechanism of action of brexpiprazole in treating psychiatric conditions 
is unknown, the pharmacology of brexpiprazole is believed to be mediated by a 
combination of high-binding affinity a nd functional activities at multiple monoaminergic 
receptors. It has modulatory activity at the serotonin and dopamine systems that 
combines partial agonist activity at serotonergic 5 -HT1A and at dopaminergic D 2 
receptors with antagonist activity at seroto nergic 5 -HT2A receptors, with similar high 
affinities at all of these receptors (inhibition constant [K i]: 0.1 - 0.5 nM). Brexpiprazole 
also shows antagonist activity at noradrenergic α 1B/2C receptors with affinity in the same 
sub-nanomolar K i range (K i: 0.2 - 0.6 nM). The 5- HT1A/D2 receptor partial agonist 
activity in combination with 5 -HT2A and α 1B/2C  receptors antagonism of brexpiprazole 
may correlate with antipsychotic and antidepressant efficacy, reduced impulsive behavior, and cognitive improvement.
10  
Please refer to the Investigator’s Brochure (IB) for more detailed information. 
Protocol 331-201-00195  
22 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  2.1 Trial Rationale  
There are currently no pharmacological treatments approved for BPD. The first-line of 
treatment is psychotherapy, including dialectic al behavior therapy to manage emotions, 
help with tolerating distress, and managing relationships.7 Pharmacotherapy is used to 
treat targeted symptoms that fall within the following categories: 1) affective 
dysregulation, mood lability, and anger, 2) impulsive and self-harming behavior, and 
3) cognitive perceptual symptoms. Based on off-label prescribing practices and on 
clinical trial data, there is evidence that atypical antipsychotics may be efficacious at 
treating patients with BPD, especially symptoms of mood, self-harm, impulsivity, and aggression. Reductions in overall BPD symptomatology have been demonstrated in 
clinical trials of quetiapine ,
11 olanzapin e,12,13,14 clozapine,15,16 and aripiprazole.17,18 
This receptor activity profile of brexpiprazole may allow for effective pharmacotherapy 
for the treatment of BPD. More specifically, the serotonergic and dopaminergic stabiliza tion and normalization provided by brexpiprazole may directly address the 
pathways implicated in the BPD features of impulse aggression (serotonergic) and emotional dysregulation and impulsivity (dopaminergic). 
The proposed 12- week, open -label trial ( Trial 331-201-00195) will be conducted  to 
evaluate the safety and tolerability of brexpiprazole for the treatment of subjects 
diagnosed with BPD. 
2.2 Background  
A complete description of the available efficacy and safety pharmacology data from 
nonclinical studies, including pharmacokinetic (PK) and toxicology studies in different 
animal species can be found in the current IB.
10 
Currently, brexpiprazole is approved in multiple countries  for use in adult patients for the 
treatment of schizophrenia, and for the use as an adjunctive therapy to antidepressants for 
the treatment of MDD. Additionally, the current clinical development program is designed to show safety and efficacy of brexpiprazole for the treatment of the following 
indications: treatment of adult post-traumatic stress disorder (PTSD), bipolar mania, 
adolescent schizophrenia, and the treatment of agitation in Alzheimer’s dementia 
(AAD).
10  
As of 17 Apr 2018, the brexpiprazole clinical development program consisted of a total 
of 74 clinical trials conducted in North America, Latin America, Europe, and Asia (66 completed and 8 ongoing). This includes 67 trials conducted under US 
Investigation al New Drug (IND) Applications (59 completed and 8 ongoing) for 
Protocol 331-201-00195  
23 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  schizophrenia, adjunctive treatment of MDD, adjunctive treatment of 
attention -deficit/hyperactivity disorder (ADHD), AAD, PTSD, or bipolar; and 7 non- US 
IND trials (7  completed and 0 ongoing) in either South Korea or Japan conducted in 
healthy subjects or subjects with schizophrenia.10  
Please refer to the current IB for a detailed summary of available clinical data.10  
2.3 Known and Potential Risks and Benefits  
As of 17 Apr  2018, a total of 9153 unique subjects were exposed to single or multiple 
doses of brexpiprazole (either alone or with another marketed drug) in US IND trials. This total includes 877 subjects in the collective phase 1 clinical pharmacology trials  
(593 healthy subjects or subjects in special populations and 284 subjects diagnosed with either schizophrenia or schizoaffective disorder [N = 236], MDD [N = 36], or ADHD 
[N = 12]) and 8276 subjects diagnosed with either schizophrenia or schizoaffective 
disorder (N = 2404), MDD (N = 5265), AAD (N = 429), ADHD (N = 155), or PTSD 
(N = 23) in the collective phase 2 and phase 3/3b trials.  
Overall, the total number of subject years of exposure (SYE) in the completed phase 1 clinical pharmacology trials (N = 877) and all phase 2 and phase 3/3b trials combined (N = 8276) was 28.5 and 3590.3 SYEs, respectively. Exposure to brexpiprazole in the 
completed phase 2 and phase 3/3b US IND trials is summarized by duration of exposure 
and indication in the current IB .
10 The majority of subjects within each of the 
5 indications have received at least 6  weeks of brexpiprazole, including 3139 subjects 
with at least 26  weeks of exposure and 1612 subjects with at least 52 weeks of exposure. 
Completed phase 2 and phase 3 clinical trials have evaluated multiple oral doses up to 
6 mg/day in subjects with schizophrenia, up to 3 mg/day when coadministered with 
marketed antidepressant t herapy in subjects with MDD, up to 3 mg/day in subjects with 
PTSD, up to 2 mg/day when coadministered with marketed stimulant therapy in subjects with ADHD, and up to 2 mg/day in subjects with AAD. Dose selection for the ongoing 
multiple -dose trials was derived from the collective safety, efficacy, and receptor 
occupancy data from completed phase 1, phase 1b, phase 2, and phase 3 trials of 
brexpiprazole. 
Protocol 331-201-00195  
24 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Overall, 9062 subjects received brexpiprazole either alone or coadministered with 
another marketed medic ation from the 59 completed brexpiprazole trials conducted under 
US INDs. Overall, 6403/9062 subjects (70.7%) reported at least 1 treatment- emergent 
adverse event ( TEAE ) compared with 1498/2781 subjects (53.9%) who received placebo 
either alone or coadmini stered with another marketed medication. The most frequently 
reported TEAEs (incidence ≥ 5% of the total brexpiprazole group and more than total 
placebo) in all subjects who received brexpiprazole were increased weight (12.1%), 
headache (9.1%), insomnia (7.8%), akathisia (7.2%), somnolence (6.2%), and dizziness (5.3%). In the total placebo group, headache (8.2%) was the most frequently reported TEAE (incidence ≥ 5% of subjects).  
Please refer to the current IB for a summary of available nonclinical and clini cal safety 
data.
10 Trial sites will receive updated versions of the IB, when available, and trial sites 
should refer to the most current version as needed. 
3 Objectives and Endpoints  
Table 3-1 Trial Objectives and Endpoints  
Objectives  Endpoints  
Primary Safety: To evaluate the 
safety and tolerability of 
brexpiprazole for the treatment of subjects with a diagnosis of BPD.
 
 Primary Safety: Frequency and severity of 
AEs.  
 
Secondary Safety:  
• Changes in: ECGs, vital signs, clinical laboratory tests including prolactin, changes in body weight, and physical examinations; 
• EPS: SAS, AIMS, and BARS;  
• Suicidal ideation and behavior will be assessed using the C- SSRS.  
Protocol 331-201-00195 
25 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 Table 3-1 Trial Objectives and Endpoints 
Objectives Endpoints 
AE = adverse event; AIMS = Abnorm al Involuntary Movement Scale; BARS = Barnes Akathisia Rating 
Scale; ;  
; 
C-SSRS = Columbia-Suicide Severity Rating Scale;  ECG = electrocardiogram;  EPS = extrapyramidal 
symptom; ET = early termination; ; 
;  
SAS = Simpson Angus Scale;  Schedule; . 
Note: The assessments from the last  scheduled treatment visit of th e previous double-blind trial will 
serve as the baseline measures for Trial 331-201-00195.  
 
Section  9.4 describes the statistical analysis of the endpoints. 
4 Trial Design 
4.1 Type/Design of Trial 
This is a 12-week, multicenter, open-label trial designed to evaluate the safety and 
tolerability of brexpi prazole treatment in adult subject s diagnosed with BPD. Subjects 
will receive 2 to 3 mg/day brexpiprazole. CCICCI CCI
CCI CCICCI
CCICCI
Protocol 331-201-00195  
26 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Enrollment into the trial will be drawn from eligible subjects who  completed the last 
treatment visit of the previous double-blind brexpiprazole BPD trials (and took the 
investigational medicinal product [ IMP] through the last scheduled treatment visit) and, 
in the investigator’s judgment, could potentially benefit from treatment with 
brexpiprazole for BPD.  
The trial will be organized as follows: 
Screening/Baseline:  Subjects will be screened for eligibility at the last scheduled 
treatment visit of the pr evious double- blind trial. Subjects will sign a separate informed 
consent form (ICF) at the last scheduled treatment visit of the pr evious double- blind trial 
for participation in this trial before any procedures specific to the open- label trial are 
perform ed. The assessments from the last scheduled treatment visit of the previous 
double- blind trial will serve as the baseline measures for this trial for any assessment that 
is not new ( unique) to the open- label trial. Medical history will be updated, if neces sary.  
Informed consent cannot be obtained after the last scheduled treatment visit of the 
previous double-blind trial without all screening/baseline assessments being repeated. If a 
subject is unable to rollover immediately, up to 3 days may be permitted between the end 
of the double-blind trial and the start of IMP in the open-label extension trial; however, this must be discussed with the medical monitor (Note: assessments from the last 
scheduled treatment visit in the previous double- blind trial that are  going to be used as 
the baseline measures for Trial 331 -201-00195 will not need to be repeated if the subject 
enters Trial  331-201-00195 within 3 days). 
Treatment Phase:  E
 ligible subjects will receive daily treatment with open -label 
brexpiprazole beginning at the screening/baseline visit, as described in Section  6.1. Visits 
will occur at the end of Weeks 2, 4, 8, and 12. Telephone contact will be made at 
Weeks  1, 6, and 10 to assess adverse events (AEs) and concomitant therapy . In addition, 
an optional telephone call or other form of communication will be made with the subject approximately 1 week (± 2 days) after the visit (eg, at Weeks 3, 5, 7, 9, and 11) to check on status. All subjects will receive up to 12  weeks of open- label treatment in this trial.  
Follow-up: Subjects will be followed for safety via telephone contact or clinic visit 
21 (±  3) days after the last dose of open- label brexpiprazole. 
See Figure 1.2-1 for a schematic of the trial design.  
Protocol 331-201-00195  
27 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  4.2 Scientific Rationale for Trial Design  
Given its clinical efficacy in treating both schizophrenia and MDD as well as its 
multimodal mechanism of action, brexpiprazole may offer added benefit to patients 
suffering from BPD. Like other psychological disorders, BPD has been linked to 
aberrations i n monoaminergic neurotransmission. While dysfunctions related to 
dopamine and serotonin have been historically cited, recent evidence has also implicated 
noradrenergic dysfunction in BPD as well.19,20,21,22 
While the precise mechanism of action of brexpiprazole in treating psychiatric conditions 
is unknown, the pharmacology of brexpiprazole is believed to be mediated by a combination of high- binding affinity and functional activities at multiple monoaminergic 
receptors, as noted in Section  2. Together, the broad pharmacological profile of 
brexpiprazole may provide for a unique treatment strategy for BPD. More specifically, the serotonergic and dopaminergic stabilization and modulation provided by brexpiprazole may directly address some of the key features and symptoms noted in the disease including impulsivity, aggression, affective instability, and suicidality. It is 
anticipated that the brexpiprazole safety profile for BPD will be comparable to the safety 
profiles of the currently approved indications.  
Trial 331-201-00195 is being conducted to evaluate the safety and tolerability of 
brexpiprazole in subjects diagnosed with BPD who have completed a double-blind BPD 
trial. 
4.3 Dosing Rationale  
The dosing paradigm of brexpiprazole to be used in Trial 331-201-00195 has been 
determined based on the dosing ranges investigated in other related psychiatric 
indications (bipolar I disorder, MDD, PTSD, and schizophrenia) and the dosing ranges 
used in the previous double-bl ind trials for th e open -label extension .
10  
In other psychiatric indications, brexpiprazole has been shown to be safe and well 
tolerated within the proposed dose range to be investigated in this trial (ie, 2 to 
3 mg/day). In addition, the effective dose range for approved indications (MDD and 
schizophrenia) is 2 to 4 mg/day; the 1 mg/day dose has not been shown to be effective. 
4.4 End of Trial Definition 
The end of trial date is defined as the last date of contact or the date of final contact 
attempt from the post- treatment follow -up page in eSource for the last subject completing 
or withdrawing from the trial.  
Protocol 331-201-00195  
28 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  4.5 Definition of Completed Subjects  
The treatment period is defined as the time period during which subjects a re evaluated for 
primary and/or secondary objectives of the trial irrespective of whether or not the subject 
actually consumed all doses of the IMP. Subjects who are evaluated at the last scheduled 
visit during the treatment period will be defined as trial completers. For purposes of this trial, subjects who complete Week 12  visit will be defined as trial completers.  
5 Trial Population 
The trial population will consist of eligible male and female subjects diagnosed with BPD and who, in the investigator’s judgment, could potentially benefit from treatment with 
brexpiprazole for BPD according to the following criteria: 
• Subjects who participated in a double- blind brexpiprazole BPD trial will be eligible 
for Trial 331 -201-00195 if they have completed the last sche duled treatment visit of 
the previous double- blind trial and did not terminate early.  
• Subjects must qualify for Trial 331-201-00195 at the last scheduled treatment visit of 
the previous double-blind trial and must be able to continue treatment without interruption between the double-blind and open- label trials  (if a subject is unable to 
rollover immediately, up to 3 days may be permitted between the end of the double-blind trial and the start of IMP in the open-label extension trial; however, this must be discussed with the medical monitor) .  
 Decisions regarding inclusion of subjects at the time of enrollment and assessment of 
subject safety throughout the trial primarily remain at the discretion of the investigator; however, the medical monitor may recommend exclusion or discontinuation of a subject based on individual subject data. 
5.1 Subject Selection and Numbering 
All subjects will retain  a unique subject identifier (ID; site number [3 digits] + subject 
number ['S' + 5 digits] that was given upon providing consent [ or assent if applicable]) 
for the previous double- blind trial.  
5.2 Eligibility Criteria  
Exceptions for eligibility criteria will not be permitted during the trial, neither by the 
investigator nor by the medical monitor. 
Protocol 331-201-00195  
29 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  5.2.1  Inclusion Criteria  
Subjects are required to meet the following inclusion criteria at the time points described 
in the schedule of assessments ( Table 1.3-1).  
1) Subjects, who completed the last treatment visit of the previous double-blind 
brexpiprazole BPD trial and who, in the opinion of the investigator, could potentially benefit from administration of brexpiprazole for the treatment of BPD.  
2) Male or female outpatients , ages 18 to 65 years, inclusive, at the time of informed 
consent of the previous double-blind brexpiprazole BPD trial. 
3) Subjects who are abl e to complete the consent process and/or consent obtained 
from a legally acceptable representative (as required by the institutional review board [ IRB]/independent ethics committee [ IEC]) prior to the initiation of any 
protocol-required procedures. 
4) Ability, in the opinion of the principal investigator, to understand the nature of the trial and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, and discontinuation of prohibited medication, and to read and understand the written word in order to be reliably rated on assessment scales. 
 
5.2.2  Exclusion Criteria  
Subjects will be excluded if they meet any of the following exclusion criteria at the time 
points described in the schedule of assessments ( Table 1.3-1).  
Sex and Reproductive Status  
1) Sexually active males or  females of childbearing potential ( FOCBP ) who do not 
agree to practic e 2 different methods of birth control or remain abstinent during 
the trial and for 30 days after the last dose of IMP. If employing birth control, 2 of 
the following precautions must be used: vasectomy, tubal ligation, intrauterine device, birth control pill, birth control implant, birth control depot injection, condom with spermicide, sponge with spermicide, or occlusive cap (vaginal diaphragm or cervical/vault cap) with spermicide. 
Consensual sexual activity that cannot biologically result in pregnancy may not be 
subject to required birth control methods, following discussion with the medical monitor. 
Male subjects must also agree not to donate sperm from trial screening/baseline  
through 30 days after the last dose of IMP. 
2) Women who are breastfeeding and/or who have a positive pregnancy test result 
prior to receiving IMP. 
Protocol 331-201-00195  
30 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Medical History and Concurrent Disease 
3) Subjects who fulfill the following criteria related to suicide and/or suicidal 
ideation at entry  are excluded:  
• Subjects who have a significant risk of committing violent acts, serious self-harm, or suicide, or those who are homicidal or considered to be a high 
risk to others, or subjects with a response of “yes” on the Columbia- Suicide 
Severity Rating Scale ( C-SSRS) Suicidal Ideation Item 5 (Active Suicidal 
Ideation with Specific Plan and Intent), OR  
• Subjects with a response of “yes” on the C- SSRS Suicidal  Behavior Items 
Actual Attempt, Interrupted Attempt, or Aborted Attempt 
• Subjects who endorse engaging in preparatory acts and/or non- suicidal 
self-injury may be included according to investigator judgment, provided the 
behavior has not increased significantly in frequency or severity during the preceding double-blind trial period, and after discussion and approval by the medical monitor.  
Note that subjects with a response of “yes” on the C- SSRS Suicidal Ideation 
Item 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan 
and Intent) may be included following discussion with the medical monitor. 
Physical and Laboratory Results 
4) Subjects with abnormal laboratory tests results, vital signs results, or electrocardiogram ( ECG ) findings, unless, based on the investigator’s judgment, 
the findings are not medically significant and would not impact the safety of the subject or the interpretation of the trial results. The medical monitor should be contacted to discuss individual cases, as needed.  
In addition, subjects with the following laboratory test and ECG results at 
screening must be excluded from the trial:  
• Platelets ≤  75000/mm
3 
• Hemoglobin ≤ 9 g/dL 
• Neutrophils, absolute ≤ 1000/mm3 
• Aspartate aminotransferase ( AST ) > 2 × the upper limit of normal ( ULN) 
• Alanine aminotransferase ( ALT ) > 2 × ULN  
• Creatine phosphokinase (CPK) > 3 × ULN, unless discussed with and 
approved by the medical monitor 
• Creatinine ≥  2 mg/dL 
• QT interval corrected for heart rate using Fridericia’s formula ( QTcF ) 
≥ 450 msec i n men and ≥  470 msec in women, unless due to ventricular 
pacing. 
Tests with exclusionary results should be repeated to ensure reproducibility of the abnormality before excluding a subject based on the criteria noted above. For ECG s, perform 3 consecutive recordings. If 2 of the 3 remain exclusionary then 
the subject must be excluded. 
Protocol 331-201-00195  
31 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  5) Subjects with a positive drug screen for cocaine or other illicit drugs are excluded 
and may not be retested or rescreened. Subjects with a positive urine drug screen resulting from use of cannabis, or prescription or over-the counter medications, or products that, in the investigator’s documented opinion, do not signal a clinical condition that would impact the safety of the subject or interpretation of the trial resul ts may continue evaluation for the trial following consultation and approval 
by the medical monitor. Subjects with positive results for alcohol use will require consultation and approval by the medical monitor in order to verify use does not indicate a substance- use disorder.  
Other  
6) Subjects with a major protocol deviation during the course of their participation in the previous double-blind brexpiprazole BPD trial. Minor deviations such as occasional visits outside of the acceptable window or a missing blood draw will not exclude a subject from participation in Trial 331-201-00195; however, continual lack of compliance with the visit schedule, trial assessments, or treatment regimen in the previous double-blind trial would be considered a major deviation that would result in exclusion from Trial 331-201-00195. If the maj or 
protocol deviation is due to the coronavirus disease of 2019 (COVID-19), eligibility for the subject to continue can be discussed with m edical monitor. The 
medical monitor should be contacted if the investigator is unsure of any subject’s eligibility.  
7) Subjects who participated in a clinical trial within 90  days prior to 
screening /baseline  (with the exception of a previous brexpiprazole double-blind 
BPD trial) or who participated in more than 2 clinical trials within a year prior to screening /baseline . 
8) Any subject who, in the opinion of the sponsor, investigator, or medical monitor, should not participate in the trial.  
 A definition of childbearing potential can be found in Section  10.3. 
Subjects must agree to restrictions to medications described in Section  6.5. No 
restrictions to activity, food, caffeine, alcohol, or tobacco or any other lifestyle 
considerations are needed during this trial. 
5.3 Lifestyle Considerations  
Not a pplicable.  
5.3.1  Meals and Dietary Restrictions  
Not applicable.  
5.3.2  Caffeine, Alcohol, and Tobacco  
Not applicable.  
Protocol 331-201-00195  
32 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  5.3.3  Activity  
Not applicable.  
5.4 Screen Failures  
A screen failure is a subject from whom informed consent is obtained and is documented 
in writing (ie, subject signs an ICF), but who is not assigned trial treatment. 
If the subject meets the definition of a screen failure in this trial, the following 
information will be recorded in eSource: 
• Date of informed consent 
• Visit date (screening/baseline  visit)  
• Demographics (collection date, birth date, sex) 
• Result of eligibility assessment 
• Screen failure date  
• Reason for screen failure  
 
Rescreening of subjects is not permitted.  
6 Trial Treatments  
6.1 Trial Treatments Administered  
The first dose of open-label brexpiprazole will be taken one day after the last dose of 
double-blind IMP is taken for the previous double-blind, brexpiprazole BPD trial so that 
treatment continues without interruption. It is anticipated that the last dose of IMP of the 
double- blind tria l will be taken the day of the treatment last  visit of the previous 
double-blind brexpiprazole BPD trial (ie, the day of the screening/baseline visit for the 
open- label trial).  If a subject is unable to rollover immediately, up to 3 days may be 
permitted b etween the end of the double-blind trial and the start of IMP in the open- label 
extension trial; however, this must be discussed with the medical monitor. 
All subjects will receive a starting dose of 1  mg/day  at the screening/baseline visit , 
followed by an increase to 2 mg/day at the end of Week  1 (Table 6.1-1 ). Subjects may 
increase their dose to 3  mg/day at the investigator’s discretion on or after the Week 2 
visit, depending on treatment response and tolerability. Subjects taking 3 mg/day may 
down- titrate to 2  mg/day based on tolerability at any time during the course of the trial. 
Subjects unable to tolerate 2 mg/day will be discontinued from the trial. Dose 
adjustments to brexpiprazole must be made in increments of 1 mg/day. Dose decreases 
Protocol 331-201-00195  
33 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  for brexpiprazole can occur at unscheduled visits and dose increases for brexpiprazole 
can only occur at scheduled visits. 
As applicable, dose changes of background antidepressant therapy (ADT) can be 
modified to achieve optimum efficacy and tolerability. Dose adjustments of ADT should not occur at the same visit as a dose adjustment of brexpiprazole and a recommended minimum of 5 days should occur between any dose adjustments of brexpiprazole or ADT 
at any point during the trial. 
Table 6.1-1 Dosing Schedule  
IMP  Screening /Baseline  - Week 1  Week 1 - Week 2  Week 2 - Week 12a 
Brexpiprazole  1 mg/day  2 mg/day  2 or 3 mg/dayb 
 
aDown titration can occur at any time due to tolerability after Week 2. The minimum dose allowed is 
2 mg/day.  
bOption to titrate to 2 or 3 mg/day (ie, 2 mg, or 3 mg) based on clinical response and tolerability; 
changes must occur in 1 mg/day increments.  
 
For information regarding the dose regimen and treatment period(s), including any 
follow-up period(s), see Section  4.1. 
6.1.1  Medical Devices  
Not applicable.  
6.2 Management of Investigational Medicinal Product  
For full details on IMP management, please refer to the brexpiprazole IB.10  
6.2.1  Packaging and Labeling 
Investigational medicinal product will be provided to the investigators and the persons designated by the investigator(s) or institution(s) by the sponsor or designated agent. The 
IMP will be supplied as blister cards.  Each blister cards  used in the dosing period will be 
labeled to clearly disclose the subject ID, compound ID, trial number, sponsor’s name 
and address, instructions for use, route of administration, and appropriate precautionary statements . 
6.2.2  Storage  
The IMP will be stored in a securely locked cabinet or enclosure. Access will be limited 
to investigators and their designees. Neither investigators nor any designees may provide IMP to any subject not participating in this protocol. 
The IMP will be stored according to the conditions indicated on the IMP label.  
Protocol 331-201-00195  
34 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  The clinical site staff will maintain a temperature log in the IMP storage area to record 
the temperature.  
6.2.3  Accountability  
The investigator or designee must maintain an inventory record of IMP (including investigational, active control, or placebo) received, dispensed, administered, and returned. Neither the investigator nor any designees may provide IMP to any subject not participating in this protocol. 
6.2.4  Returns and Destruction 
The IMP will be destroyed by the clinical trial site. The IMP may o nly be destroyed by 
the trial site(s), if approved by the sponsor and if the IMP destruction meets all local 
regulations. Accountability of the IMP must be completed and verified by the assigned trial monitor prior to destruction. The trial site(s) may utilize qualified third -party 
vendors for IMP destruction.  
6.2.5  Reporting of Product Quality Complaints  
A Product Quality Complaint (PQC) is any written, electronic, or oral  communication by 
a healthcare professional, consumer, subject, medical representative, regulatory agency, 
partner, or other third party that alleges deficiencies related to the identity, quality, 
durability, reliability, safety, effectiveness, or performance of a medical device or 
medicinal  product or a falsified, tampered, or diverted product after it is released for 
distribution  to a clinical trial. Examples include, but are not limited to, communications 
involving: 
• Failure/malfunction of a product to meet any of its specifications 
• Incorrect or missing labeling  
• Packaging issues (eg, damaged, dirty, crushed, missing product) 
• Blister defects (eg, missing, empty blisters)  
• Bottle defects (eg, under/over- fill, no safety seal)  
• Vial defects  
• Product defect (eg, odor, chipped, broken, embossing illegible) 
• Loss or theft of product 
 
Protocol 331-201-00195 
35 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 6.2.5.1 Eliciting and Reporti ng Product Quality Complaints 
The investigator or designee must record all PQCs identified through any means from the 
receipt of the IMP from the sponsor or sponsor’s designee, through and including 
reconciliation and up to dest ruction, including subject dos ing. The investigator or 
designee must notify the sponsor (or sponso r’s designee) by e-mail within 24 hours of 
becoming aware of the PQC according to the procedure outlined below. 
x Send PQC reporting information to the OPDC IMP complaints mailbox email: 
 
Also indicate whether or not the complaint sample is available for return. 
 
Identification of a PQC by the subject should be reported to the site investigator, who 
should then follow the reporting mechanism above. 
6.2.5.2 Information Required for Reporting Purposes 
x Description of complaint 
x Reporter identification (eg, subj ect, investigator, site, etc.) 
x Reporter contact information (eg, addr ess, phone number, e-mail address) 
x ID of material (pr oduct/compound name, coding) 
x Clinical protocol reference (number and/or trial name) 
x Dosage form/strength (if known) 
x Pictures of complaint sample (if available) 
x Availability of complaint sample for return 
 
6.2.5.3 Return Process 
Indicate during the report of the PQC if the complaint sample is available for return. If 
the complaint sample is available for return, the return instructions will be provided by the sponsor. 
It must be documented in the site accountab ility record that a complaint sample for a 
dispensed kit has been forwarded to th e sponsor for complaint investigation. 
6.2.5.4 Assessment/Evaluation 
Assessment and evaluation of PQCs  will be handled by the sponsor. 
6.3 Measures to Minimize/Avoid Bias 
This trial is open-label. CCI
Protocol 331-201-00195  
36 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  6.4 Subject Compliance  
Responsible trial personnel will dispense the IMP (ie, brexpiprazole). Accountability and 
compliance verification should be documented in the subject’s trial records. Subjects 
must be counseled on the importance of taking the IMP as directed at all trial visits. If 
poor compliance continues (eg, multiple missed doses resulting in less than 80% overall compliance at any point in the trial), discontinuation of the subject from the trial should be considered. Subjects who habitually miss visits or habitually attend visits outside of 
the protocol- defined visit wind ow are also noncompliant and should be considered for 
discontinuation. The medical monitor should be contacted if the investigator is uncertain 
whether a subject’s lack of compliance merits discontinuation from the trial.  
6.5 Concomitant Medications or Therapi es 
The investigator will record all medications and therapies taken by the subject from the 
screening/baseline visit  through the end of the evaluation period (defined as the time 
period during which subjects are evaluated for primary and/or secondary objec tives) in 
eSource. The investigator will also record all medications and therapies taken by the 
subject for treatment of an AE or which caused an AE until the end of the trial (defined as 
the last date of contact or date of final contact attempt) in eSource. 
For concomitant medications, the following will be recorded in eSource: medication, 
indication, dose, frequency, route, start date, and end date. For concomitant therapy, the following will be recorded in eSource: therapy, indication, start date, end date, and 
frequency.  
6.5.1  Prohibited Medications  
Table 6.5.1-1 lists all medications prohibited during the trial, including exceptions, where 
appropriate. Th is table is consistent with the prohibited medications across the 
double-blinded trials. However, in this open-label extension, exceptions to prohibited medications or dose adjustments to allowed medications (ie, benzodiazepines) may be considered on a cas e-by-case basis following discussion with the medical monitor. This 
will provide greater flexibility in treatment as subject needs arise.  
Protocol 331-201-00195  
37 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Table 6.5.1 -1 List of Medications Prohibited During the Trial  
1. Psychotropic agents including, but not limited to, the following:  
a) Antipsychotics, including depot or long- acting injectable formulations  
b) Anticonvulsants  (except for gabapentin when used to treat anxiety or pain, after discussion 
with the medical monito r) 
c) Monoamine oxidase inhibitors, tricyclic antidepressants,a trazodone,a nefazodone, fluoxetine 
(> 60 mg/day), and paroxetine (>  50 mg/day)  
d) Mood stabilizers (ie, lithium)  
e) Benzodiazepine use is restricted to chronic, stable treatment or when used to manage TEAEs 
such as agitation and anxietyb 
f) Hypnotics, including ramelteonc 
g) Stimulants and atomoxetine  
h) Opioid analgesics, unless approval is obtained from the medical monitor. Approval for 
opioid use may be considered for a documented and clinically appropriate indication 
(eg, episodic pain condition, tooth extraction) if prescribed at a medically appropriate dose 
and frequency. Buprenorphine is  also excluded . 
i) Nutritional supplements and non- prescription herbal preparations with central  nervous 
system effects (eg, St. John’s Wort, omega -3 fatty acids, kava extracts, gamma -aminobutyric 
acid supplements, etc)  
j) Disulfiram  
k) Prazosin - allowed if currently being taken for an appropriate indication at a stable dose. 
Should be continued thr oughout trial participation . 
2. Investigational agents  
3. CYP2D6 inhibitors or CYP3A4 inhibitors and inducers. Selected CYP2D6 inhibitors are: 
celecoxib, hydroxyzine, chloroquine, methadone, chlorpheniramine, moclobemide, clemastine, clomipramine, pyrilamine, diphenhydramine, quinidine, terbinafine, halofantrine,  and 
tripelennamine. Selected CYP3A4 inhibitors are: amiodarone, amprenavir, indinavir, aprepitant, itraconazole, chloramphenicol, ketoconazole, cimetidine, nefazodone, clarithromycin, nelfinavir, clotrimazole (if used orally), quinupristin/dalfopristin, d elavirdine, ritonavir, diltiazem, 
saquinavir, erythromycin, troleandomycin, fluconazole, and verapamil. Selected CYP3A4 
inducers are: carbamazepine, oxcarbazepine, phenytoin, dexamethasone, primidone, efavirenz, rifampin, nevirapine, St. John’s Wort, phenobarbitol, and troglitazone. The medical monitor 
should be consulted for any questions regarding the potential for PK  interactions with 
concomitant medications used by subjects during the trial.  
4. Barbiturates  
5. Beta receptor antagonistsd  
6. Anticholinergic agents are prohibited within 8 hours of schedule d EPS scale assessments.  
CYP = cytochrome P450.  
aUnless they are being used for sleep management (further discussion with the medical monitor is 
required before allowing these medications). 
bSee Section  6.5.2 . 
cChronic, stable (ie, regularly scheduled maintenance dose that has not changed during the previo us 
double -blind trial) use of non -benzodiazepine sleep aids (ie, zolpidem, zaleplon, and eszopiclone 
only) is permitted for the management of sleep but not on the same day as administration of a benzodiazepine, regardless of indication. Intermittent use of  specific non -benzodiazepine sleep aids is 
permitted for the short- term management of TEAEs related to sleep problems.
 For the 
non-benzodiazepine sleep aids, only 1 of the listed medications that are approved for this indication in 
the respective countries  should be used and the country- specific prescribing information is to be used 
to determine the maximum allowable daily dose for the treatment of insomnia. Non- benzodiazepine 
sleep aids must not be administered within 8 hours prior to scheduled efficacy and safety assessments, including EPS scales.  Other changes to hypnotic medications must be discussed with the medical 
monitor.  
Protocol 331-201-00195  
38 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  dPropranolol is permitted for akathisia or tremor up to a maximum of 20 mg 3 times daily (total of 
60 mg/day). Propranolol must not be administered within 8 hours prior to scheduled efficacy and 
safety assessments, including EPS scales.  Other changes to beta receptor antagonists must be 
discussed with the medical monitor.  
 
6.5.2  Benzodiazepine Use During the Trial  
Chronic, stable (ie, regularly scheduled maintenance dose that has not changed during the 
previous double-blind trial) use of specific oral benzodiazepines is permitted for the treatment of anxiety up to a maximum of 2 mg/day lorazepam (or equivalent) or 1 mg/day clonazepam in divided doses. Intermittent use of specific oral benzodiazepines 
is permitted for the short term management of TEAEs up to a maximum of 2 mg/day 
lorazepam (or equivalent) or 1 mg/day clonazepam in divided doses. Short- acting 
benzodiazepines are to be used whenever possible. In countries where no short- acting 
benzodiazepines are commercially available, use of oral clonazepam may be acceptable if 
prior authorization is obtained from the medical monitor. The following guide should be 
used to determine approximate lorazepam equivalents: 1 mg lorazepam = 15 mg 
oxazepam = 0.5 mg alprazolam = 5 mg diazepam = 0.5 mg clonazepam. If required for 
intermittent treatment of agitation, the prescribed benzodiazepine should be discontinued 
as soon as t he AE for which it was initiated subsides, as per the investigator’s discretion 
to avoid any withdrawal effects. Benzodiazepines should not be administered within 8 hours prior to scheduled efficacy and safety assessments, including extrapyramidal 
symptom ( EPS) scales. Investigators are encouraged to delay scale administration until 
8 hours have elapsed, if at all possible. However, if delaying administration of efficacy 
and safety scales is not feasible, the scales should still be administered and the use of benzodiazepine documented, including a notation of the drug name, dose, and time of 
administration in  eSource. For subjects entering the trial on regularly  scheduled 
maintenance doses of benzodiazepines, routine doses may be taken at scheduled times 
per investigator instructions as long as the drug name, dose, date, and time taken are 
clearly documented in eSource.  
6.5.3  Permitted Medications or Therapies  
Initiation of treatment with new medications or initiation of dose changes in current medications should not occur without discussion with the medical monitor. For subjects who are on ADT treatment at trial entry, dose changes of brexpiprazole and dose changes of ADT, if applicable, should not occur at the same visit and should have a minimum of 
5 days occurring between a dose change. Doses of paroxetine cannot exceed 50 mg/day 
and doses of fluoxetine cannot exceed 60 mg/day. 
Protocol 331-201-00195  
39 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Initiation of psychotherapy or change in current psychotherapy treatment during the trial 
may be considered after consultation with the m edical monitor.  
6.5.4  Rescue Medications  
Not applicable.  
6.6 Intervention after the End of the Trial  
Not applicable.  
7 Stopping Rules, Withdrawal Criteria, and Procedures  
7.1 Entire Trial or Treatment  
If the sponsor terminates or suspends the trial for any reason, prompt notification will be given to investigators, IRBs/IECs, and regulatory authorities in accordance with regulatory requirements. 
7.2 Individual Site  
Individual trial site participation may be discontinued by the sponsor, the investigator, or 
the IRB/IEC if judged to be necessary for medical, safety, regulatory, ethical or other reasons consistent with applicable laws, regulations, and Good Clinical Pra ctice ( GCP ). 
The investigator will notify the sponsor promptly if the trial is terminated by the investigator or the IRB/IEC at the site.  
7.3 Individual Subject Discontinuation 
7.3.1  Treatment Interruption  
All attempts should be made to avoid treatment interruptions during the trial. If a 
subject’s IMP treatment must be interrupted for medical or surgical reasons; liver test abnormalities; use of a prohibited concomitant medication; or other reasons (eg, hospital admission for an invasive procedure, a major medical condition, surgery, dental work, or 
a temporary situation that prevents subject compliance with the IMP dosing schedule), 
the subject’s  IMP should be resumed as early as the situation allows (see Section  7.3.4). 
If > 4 consecutive doses of IMP are missed, a discussion should occur with the medical 
monitor to determine if the subject should be discontinued f rom the trial as a result of the 
treatment interruption.  
Protocol 331-201-00195  
40 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  7.3.2  Treatment Discontinuation 
After starting open- label IMP , a subject may stop treatment permanently for a variety of 
reasons. Treatment discontinuations may be initiated by a subject who is not satisfi ed 
with treatment or may become medically necessary due to AEs, required treatment with a 
disallowed medication or therapy, or other issues, as determined by the investigator. However, each investigator must comprehensively review the circumstances and off er the 
subject options for continued treatment to the degree possible as described in 
Section  7.3.5. 
7.3.3  Documenting Reasons for Treatment Interruption or 
Discontinuation 
A subject may temporarily interrupt or discontinue IMP for the reasons listed below: 
• Adverse event  
− Subject decides to discontinue because of annoy ance or discomfort due to a 
nonserious AE which is not otherwise determined to be an undue hazard 
− Continuing IMP places the subject at undue risk as determined by the investigator 
(eg, a safety concern that is possibly, probably, or likely related to IMP) 
• Serious adverse event (SAE)  
• Other potentially IMP -related safety concerns or AEs 
• Death  
• Lack of efficacy  
• Lost to follow-up 
• Noncompliance with IMP 
• Physician decision 
• Pregnancy (see Section  10.3) 
• Protocol deviation 
• Site terminated by sponsor 
• Trial  terminated by sponsor 
• Withdrawal by subject 
 
If the subject  temporarily interrupts or discontinues IMP due to an AE, the investigator, 
or other trial personnel, will make every effort to follow the event until it has resolved or 
stabilized. Follow-up procedures in Section  7.3.1 and Section  7.3.2 must be followed. 
Protocol 331-201-00195  
41 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  7.3.4  Withdrawal of  Consent  
All subjects have the right to withdraw their consent from further participation in the trial 
at any time without prejudice. Subjects cannot withdraw consent for use of data already 
collected as part of the trial, but only for future participation. The investigator can also 
discontinue a subject’s participation in the trial at any time if medically necessary. Unless the subject provides their written withdrawal of consent or there is other written documentation by the investigator confirming the subject’s verbal intent to completely 
withdraw from the trial, subjects should be followed for all protocol- specified evaluations 
and assessments, if possible. 
Complete withdrawal of consent requires a subject’s refusal of ALL of the following 
methods of follow-up: 
• Participation in all follow -up procedures specified in the protocol (whether in- clinic, 
by telephone, or by an in- home visit).  
• Participation in a subset of protocol specified follow-up procedures (by a frequency 
schedule and method, as agreed by subject and staff).  
• Contact of the subject by trial personnel, even if only by telephone, to assess current medical condition, and obtain necessary medical or laboratory reports relevant to the trial’s objectives.  
• Contact of alternative person(s) who have been designated in source records as being available to discuss the subject’s medical condition, even if only by telephone, mail, or e-mail (eg, family, spouse, partner, legal representative, friend, neighbor, or 
physician). 
• Access to medical information from alternative sources (eg, hospital/clinic medical records, referring doctor’s notes, public records, dialysis, transplantation or vital registries, social media sources).  
 
Withdrawal of consent is a critical trial event and , therefore, should be approached with 
the same degree of importance and care as is used in initially obtaining informed consent. 
The reasons for a subject’s intended withdrawal need to be completely understood, 
documented, and managed to protect the rights of the subject and the integrity of the trial. 
A subject may initially express their desire to interrupt or modify or discontinue IMP administration, which is not equivalent to a complete withdrawal of consent for further participation (see Section  7.3.1 and  Section  7.3.2, respectively ). A subject may, however, 
indicate that further trial participation is creating a burden on their work, school, or social schedule. Therefore, the investigator should follow the procedures outlined in Section  7.3.3 to determine if the subject can continue participation in the trial if 
modifications to his/her treatment and/or schedule of assessments can be accommodated. 
Protocol 331-201-00195  
42 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Only subjects who withdraw their permission for all of the above methods of follow-up 
are considered to have completely withdrawn their consent to participate in the trial.  
7.3.5  Procedures to Encourage Continued Trial Participation 
In all cases of impending IMP discontinuation or consent withdrawal, investigators will be instructed to meet and discuss (without undue coercion) with the subject their options of continuing in the trial, preferably on therapy. The investigator should ensure understanding and documentation of the reasons for the subject’s desire to withdraw 
consent. 
7.4 Definition of Subjects Lost to Follow -up 
Subjects who cannot be contacted on or before Week 12 visit during the treatment period, 
who do not have a known reason for discontinuation (eg, withdrew consent or AE), and for whom a survival status at the end of the trial cannot be determined will be classified 
as “lost to follow -up”. Survival status can be determined from a variety of sources, either 
by obtaining acceptable documentation for death (ie, death certificate, medical records, 
public records, statement by a family member or primary care physician) or acceptable documentation for life (ie, direct cont act with the subject, medical records, successful 
telephone contact with the subject, statement by a family member or primary care physician, or public records). 
The site will make 3 documented attempts to contact the subject by telephone and in the 
event the site is unable to reach the subject by telephone, the site will attempt to contact 
the subject via certified mail or an alternative similar method, where appropriate, before 
assigning a “lost to follow-up” status. 
If the subject was classified as “lost  to follow- up”, “Were you able to contact the 
subject?”, “Date of contact/Date of final contact attempt” and “Contact method” will be 
recorded in the source documents. 
8 Trial Procedures 
Each subject in this trial is expected to participate in the following periods of the trial (approximate durations listed), for approximately 15 weeks: 
• Eligibility screening period (1 day) (If a subject is unable to rollover immediately, up 
to 3 days may be permitted between the end of the double-blind trial and the start of IMP in the open-label extension trial; however, this must be discussed with the medical monitor.)  
• Treatment period (12 weeks) 
• Post- treatment follow -up period (21 ± 3 days) 
Protocol 331-201-00195 
43 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020  
Eligible subjects from the previous double-blind trials will be able to roll over into this 
open-label extension trial. Overall, the trial duration from first ICF signed to the final 
subject assessment is expected to be several years. 
The assessments to be conducted during th e trial are summarized in Table 1.3-1. 
8.1 Efficacy Assessments 
It is required that trained and experienced clinicians administer all rating scales. The 
number of raters within each trial site should be kept to a minimum. All efforts will be 
made to ensure that the same clinician administers the scales for a given subject. 
Notations in the subject’s trial records should substantiate the ratings. Training, 
certification, and materials for rating will be provided by OPDC or designee.  
Subject assessment recordings are summarized in Section  8.10. 
CCI
Protocol 331-201-00195 
44 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 8.2 Pharmacokinetic Assessments 
Not applicable. 
8.3 Pharmacodynamic Assessments 
Not applicable. 
8.4 Pharmacogenomic Assessments 
Not applicable. CCI
Protocol 331-201-00195  
45 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  8.5 Biomarker Assessments 
Not applicable.  
8.6 Future Biospecimen Research Samples  
Not applicable.  
8.7 Safety Assessments  
Details pertaining to the definitions, collection, reporting, and follow-up of AEs are 
described in Section  8.8. 
8.7.1  Clinical Laboratory Assessments  
Clinical laboratory samples will be collected at the time points described in the schedule of assessments ( Table 1.3-1) to perform the clinical laboratory assessments described in 
Section  10.2. Refer to Se ction  10.5 for criteria for identifying laboratory values of 
potential clinical relevance.  
A central laboratory designated by the sponsor will be used for all laboratory testing (hematology [including H bA1c], serum chemistry [including prolactin], and urinalysis) 
required during the trial. The central laboratory should be used for all laboratory testing whenever possible (including unscheduled and follow- up, if needed). In cases where an 
immediate result is required for a particular laboratory test, the sample should be divided and sent to both a local laboratory and the designated central laboratory. Subjects should 
be fasting for a minimum of 8 hours prior to the blood draws, if possible. If fasting blood 
samples are not feasible at screening /baseline , nonfasting blood samples may be obtained 
initially for determining eligibility for the trial and need to be repeated at the next visit at the discretion of the investigator. Additional urine and blood samples may be collected 
for further evaluation of safety as warranted by the investigator’s judgment. Reports from 
the central laboratory should be filed with the source documents for each subject. The central laboratory will provide laboratory results to the sponsor electronically. 
Any value outside the normal range will be flagged for the attention of the investigator 
who must indicate whether or not a flagged value is of clinical significance. If one or more values are questionable, the test(s) may be repeated. If the result of any  test (or 
repeat test, if done) is indicated as clinically significant in the samples taken at 
screening /baseline, the subject will NOT be enrolled into the trial without the permission 
of the medical monitor. In addition, unscheduled laboratory tests should be performed if 
clinically significant abnormalities are observed. Unscheduled laboratory tests may be repeated at any time at the discretion of the investigator for appropriate medical care. 
Protocol 331-201-00195  
46 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Refer to Appendix 5 ( Section  10.5) for criteria for identifying values of potential clinical 
relevance.   
The total volume of blood to be collected during the trial will be documented in the ICF. 
A pregnancy test will be conducted in F OCBP  (refer to Section  10.3 for definition) prior 
to trial intervention; results must be available prior to the administration of the IMP. 
Pregnancy tests can be performed at any point during the trial if pregnancy is sus pected.  
8.7.2  Physical Examination  
Physical examinations will be performed at the time points described in the schedule of assessments ( Table 1.3-1 ). 
A comple te physical examination will consist of measurement of height and waist 
circumference and a review of the following body systems: head, eyes, ears, nose, and 
throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosa. At 
screening /baseline, height will be measured with a stadiometer, measuring stick or tape. 
Repeat measurement of height is not required at the physical examinations scheduled for the Week 12 /early termination ( ET) visit. Waist circumference will be measured at each 
physical examination (screening /baseline  and Week 12/ET), using the provided 
measuring tape. The following procedures will aid in the standardization of these measurements:  
• The subject should be minimally clothed (ie, lightweight clothing; no heavy 
overgarments). 
• Waist circumference should be recorded before a subject’s meal and at approximately the same time at each visit.  
• Measurement will be accomplished by locating the upper hip bone and the top of the right iliac crest and placing a weighted meas uring tape in a horizontal plane around 
the abdomen at the level of the crest. Before reading the tape measure, the assessor should assure that the tape is snug, but does not compress the skin, and is parallel to 
the floor. The measurement is to be made at the end of a normal exhalation.
24  
 
The investigator (or designee) is responsible for performing the physical examination. If 
the appointed designee is to perform the physical examination, he or she must be permitted b y local regulations and his or her name must be included on the delegation of 
authority log. Whenever possible, the same individual should perf orm all physical 
examinations. Any condition present at the post- treatment physical examination that was 
not present at the baseline examination should be documented as an AE and followed to a satisfactory conclusion. 
Protocol 331-201-00195  
47 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  8.7.3  Vital Signs  
Vital signs will be collected at the time points described in the schedule of assessments 
(Table 1.3-1 ). Subjects should be monitored for potentially clinically significant vital 
signs values ( Section  10.9).  
Vital sign measurements will include body weight, body temperature, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart  rate. The following guidelines 
will aid in the standardization of body weight measurements: 
• The same scale should be used to weigh a given subject each time, if possible. 
• Scales should be calibrated and reliable; scales should be at zero just prior to each 
subject’s weigh -in session.  
• A subject should void prior to being weighed and be minimally clothed (ie, no shoes or heavy overgarments). 
• Weight should be recorded before a subject’s meal and at approximately the same time at each visit.  
 Blood pressure and heart  rate measurements will be made in the supine and standing 
positions after the subject has been lying for at least 3 minutes. The supine measurements 
will be performed first, followed by standing.  
Subjects with uncontrolled hypertension (screening /baseline  DBP > 95 mmHg in any 
position) or symptomatic hypotension at screening/ baseline are excluded from the trial as 
are subjects with orthostatic hypotension, which is defined as a decrease of ≥  30 mmHg 
in SBP or a decrease of ≥  20 mmHg in DBP within 3 minutes of standing compared to 
the previous supine blood pressure or development of symptoms. In addition, subjects 
should be excluded if they have any other vital sign measurement at screening/ baseline 
that, in the investigator’s judgment, is medically significant in that it would impact the 
safety of the subject or the interpretation of the trial results. However, any abnormal 
screening /baseline vital sign result(s) considered to be clinically significant should be 
repeated to confirm the fin ding(s) before excluding the subject from the trial.  
8.7.4  Electrocardiogram  
Electrocardiograms will be performed at the time points described in the schedule of 
assessments ( Table 1.3-1 ). Subjects should be monitored for potentially clinically 
significant ECG results ( Section  10.7).  
Electrocardiogram recordings will be obtained after the subject has been supine and at 
rest for at least 5 minutes. Additional ECGs may be obtained at the investigator’s 
discretion and should always be obtained in the event of an ET. The principal investigator 
Protocol 331-201-00195  
48 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  (or qualified designee) will review, sign, and date each ECG reading, noting whether or 
not any abnormal results are of clinical significance. The ECG will be repeated if any 
results are considered to be clinically significant. A central ECG service w ill be used for 
reading all ECGs in order to standardize interpretations for the safety analysis. 
Rollover subjects will be enrolled in trial based on the screening/baseline ECG results 
from the trial site. If at screening /baseline , according to the investigator's judgment, any 
abnormal ECG finding is deemed medically significant (impacting the safety of the subject or the interpretation of the trial results), the subject should be excluded from the trial. Abnormal results for ECGs should be repeated once a t screening /baseline  with 
3 consecutive ECG recordings to ensure reproducibility of the abnormality before 
excluding a subject based on the criteria noted above. Each ECG recording should be 
taken approximately 5 minutes apart (the ECG result reported will be evaluated at each time point). The central ECG service will provide the corrections for the 3 ECGs performed.  If the screening/baseline ECG results from the central reader, when available, 
indicate a QTcF ≥  450 msec in men and ≥  470 msec in women (unless due to ventricular 
pacing at screening/baseline), the investigator must contact the medical monitor to discuss the subject's continued participation in the trial. 
8.7.5  Suicidality Monitoring  - Columbia -Suicide Severity Rating Scale  
Suicidality monitoring will occur at the time points described in the schedule of 
assessments ( Table 1.3-1 ). 
Suicidality will be monitored during the trial using the C -SSRS. The “ Since Last Visit” 
version of the scale will be completed at all visits for all subjects . Any subject with active 
suicidal ideation  and intent at entry or who has engaged in prohibited suicidal behaviors, 
or who, in the clinical judgment of the investigator , presents a serious risk of suicide 
should be excluded from the trial (see Section  5.2.2).  
8.7.6  Other Safety Variables 
It is required that an adequately trained and experienced clinician administer the safety assessments, including the EPS scales ( Simpson Angus Scale [ SAS], Abnormal 
Involuntary Movement Scale [ AIMS ], and Barnes Akathisia Rating Scale [ BARS ]). The 
number of raters within each trial site  should be kept to a minimum. All efforts will be 
made to ensure that the same clinician administers the scales for a given subject. Notations in the subject’s trial records should substantiate the ratings. Training and 
materials for rating will be provided by a rater training group. 
Protocol 331-201-00195  
49 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  8.7.6.1  Simpson Angus Scale  
The SAS25 consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, 
shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, 
salivation, and akathisia). Each item will be rated on a 5 -point scale, with a score of zero 
representing absence of symptoms and a sc ore of 4 re presenting a severe condition. The 
SAS total score is the sum of the scores for all 10 items. Anticholinergics, propranolol, 
benzodiazepines, and non-benzodiazepine sleep aids are not permitted within 8 hours of 
scale administration  (see Section  6.5.1). Investigators are encouraged to delay scale 
administration until the required time frame has elapsed, if at all possible. However, if 
delaying administration of the scale is not feasible, the SAS should still be administered and the use of the medication documented, including a notation of the drug name, dose, 
and time of administration in  eSource.  
8.7.6.2  Abnormal Involuntary Movement Scale  
The AIMS
23 assessment consists of 10 items describing symptoms of dyskinesia. Facial 
and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk 
movements (item 7) will be observed unobtrusively while the subject is at rest (eg, in the 
waiting room), and the investigator will also make global judgments on the subjec t’s 
dyskinesias (items 8 through 10). Each item will be rated on a 5 -point scale, with a score 
of zero representing absence of symptoms (for item 10, no awareness), and a score of 4, 
indicating a severe condition (for item 10, awareness, severe distress). For this scale, the 
subject is to be sitting on a hard, firm chair. In addition, the AIMS includes 2 yes or no 
questions that address the subject’s dental status. Anticholinergics, propranolol, benzodiazepines, and non-benzodiazepine sleep aids are not permitted within 8 hours of 
scale administration  (see Section  6.5.1). Investigators are encouraged to delay scale 
administration until the required time frame ha s elapsed, if at all possible. However, if 
delaying administration of the scale is not feasible, the AIMS should still be administered 
and the use of the medication documented, including a notation of the drug name, dose, 
and time of administration in  eSource.   
The AIMS Movement Rating Score is defined as the sum of items 1 through 7 (ie, items 
1 through 4, facial and oral movements; items 5 and 6, extremity movements; and item 7, trunk movements). 
Protocol 331-201-00195  
50 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  8.7.6.3  Barnes Akathisi a Rating Scale 
The BARS26 consists of 4 items related to akathisia: objective observation of akathisia by 
the investigator, subjective feelings of restlessness by the subject, subjective distress due 
to akathisia, an d global cli nical assessment of akathisia. The first 3 items will be rated on 
a 4-point scale, with a score of zero representing absence of symptoms and a score of 3 
representing a severe condition. The global clinical evaluation will be made on a 6-point 
scale, with zero representing absence of symptoms and a score of 5 representing severe akathisia. To complete this scale, subjects will be observed while they are seated and then 
standing for a minimum of 2 minutes in each position. Symptoms observed in ot her 
situations (eg, while engaged in neutral conversation or engaged in othe r activity) may 
also be rated. Subjective phenomena are to be elicited by direct questioning. 
Anticholinergics, propranolol, benzodiazepines, and non- benzodiazepine sleep aids are 
not permitted within 8 hours of scale administration (see Section  6.5.1). Investigators are 
encouraged to delay scale administration until the required time frame has elapsed, if at 
all possible. However, if delaying administration of the scale is not feasible, t he BARS 
should still be administered and the use of the medication documented, including a notation of the drug name, dose, and time of administration in  eSource. 
8.8 Adverse Events  
8.8.1  Definitions  
An AE is defined as any untoward medical occurrence in a clinical trial subject 
administered an IMP and which does not necessarily have a causal relationship with this 
treatment. Adverse events would not include information recorded as medical history at screening /baseline  for pre -planned procedures for which the underlying condition was 
known and no worsening occurred. An adverse reaction is any untoward and unintended 
response to an IMP related to any dose administered. 
A suspected adverse reaction is any AE for which there is a reasonable possibility that the 
IMP caused the AE. For the purpose of IND safety reporting, “reasonable possibility” means there is evidence to suggest a causal relationship between the IMP and the AE. 
Suspected adverse reaction implies a lesser degree of certainty about causality.  
Treatment -em
 ergent AEs  are defined as AEs with an onset date on or after the start of 
open- label treatment. In more detail, TEAEs are all AEs  which started after start of 
open- label IMP treatment; or if the event was continuous from baseline and was 
worsening, serious, IMP related, or resulted in death, discontinuation, interruption or 
reduction of IMP. 
Protocol 331-201-00195  
51 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  An SAE  includes any event that results in any of the following outcomes: 
• Death  
• Life-threatening; ie, the subject was, in the opinion of the investigator, at immediate 
risk of death from the event as it occurred. It does not include an event that, had it 
occurred in a more severe form, might have caused death. 
• Persistent or significant incapacity/disability or substantial disruption of the ability to conduct normal life functions. 
• Requires inpatient hospitalization or prolongs hospitalization. 
− Hospitalization itself should not be reported as an SAE; whenever possible the 
reason for the hospitalization should be reported. 
− Hospitalizations or prolonged hospitalizations for social admissions (ie, those 
required for reas ons of convenience or other non medical need) are not considered 
SAEs.  
− Prescheduled hospitalization to address a condition that has existed prior to the signing of the ICF should not be considered an SAE.  
• Congenital anomaly/birth defect. 
• Other medically significant events that, based upon appropriate medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above; eg, allergic bronchospasm requiring intensive treatment in an emergency room or home, blood dyscrasias or convulsions that do not result in hospitalization, or the development of drug dependency or drug abuse.  
 Nonserious AEs are all AEs that do not meet the criteria for a "serious" AE.  
Adverse Events of Special Interest (AESIs) : A noteworthy event for the particular 
product/IMP or class of products that a sponsor may wish to monitor carefully. All AESIs 
are to be reported as immediately reportable events ( IREs ). 
Immediately Reportable Event:   
• Any SAE.  
• Any AE related to occupational exposure. 
• Any AESIs ( Pathological Gambling and Other Compulsive Behaviors) 
• Potential serious hepatotoxicity (see Section  8.8.6 ). 
• Pregnancies are also defined as IREs. Although normal pregnancy is not an AE, it 
will mandate IMP discontinuation and must be reported on an IRE form and the 
Pregn ancy Surveillance Form(s) to the sponsor. Pregnancy will only be documented 
on the AE page in eSource if there is an abnormality or complication. This includes pregnancy of the subject or the partner of the subject. 
 
Protocol 331-201-00195  
52 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Clinical Laboratory Test Value Changes : It is the investigator’s responsibility to review 
the results of laboratory tests for each individual subject as they become available. This 
review will be documented by the investigator’s dated signature on the laboratory report. 
The investigator may repeat the laboratory test or request additional tests to verify the results of the original laboratory tests. If this laboratory value is considered medically relevant (ie, clinically significant) by the investigator (subject is symptomatic, requirin g 
corrective treatment or further evaluation), or if the laboratory value leads to discontinuation, and/or fulfills a seriousness criterion, this is considered an AE.  
Severity:  Adverse events will be graded on a 3- p
 oint scale and reported as indicated in 
eSource. The severity of an adverse experience is defined as follows: 
1 = Mild:   Discomfort noticed, but no disruption to daily activity. 
2 = Moderate:  Discomfort sufficient to reduce or affect normal daily activity.  
3 = Severe:  Inability to work or perfor m normal daily activity.  
IMP Causality: Assessment of causal relationship of an AE to the use of the IMP is 
defined as follows: 
Related :  There is a reasonable possibility of a temporal and causal 
relationship between the IMP and the AE. 
Not Related :  Ther e is no temporal or causal relationship between the IMP and 
the AE.  
 
8.8.2  Eliciting and Reporting Adverse Events  
The investigator will regularly assess subjects for the occurrence of AEs. To avoid bias in 
e
liciting AEs, subjects should be asked the nonleading question: “How have you felt 
since your last visit?” All  AEs (serious and nonserious) reported by the subject must be 
recorded on the source documents provided by the sponsor and in eSource. Adverse event collection will begin after a subject signs the ICF.  
Medical terminology should be used for AE reporting. Adverse events should be reported a
s a single unifying diagnosis whenever possible or, in the absence of a unifying 
diagnosis, as individual signs or symptoms. 
Exacerbation or disease progression  should be reported as an AE only if there are 
unusual or severe clinical features that were not present, or experienced earlier, or not 
expected based on the course of the condition.  
Protocol 331-201-00195  
53 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  In addition, the sponsor must be notified immediately by telephone, fax, or e-mail of any 
IREs according to the procedure outlined below, in Section  8.8.3. Special attention 
should be paid to recording hospitalization and concomitant medications. 
Adverse event, s tart date, end date, seriousness, severity, r elationship to trial treatment 
(IMP Causality), a ction taken with trial treatment and outcome will be recorded on the 
source documents and in eSource. 8.8.3  Immediately Reportable Events  
The investigator must immediately report (within 24 hours), using an IRE form, after 
h
e/she or site personnel become aware of any IRE (SAE, AE related to occupational 
exposure, AESI, potential serious hepatotoxicity, or confirmed pregnancy), by telephone, 
fax, or e-mail to the sponsor or designee using the contact information on the cover page 
of this protocol (Please note that the IRE form is NOT the AE page in eSource.).  
8.8.4  M edical Device Incidents (Including Malfunctions)  
Not applicable.  
8.8.5  Adverse Events of Special Interest  
The new onset or exacerbation of “Pathological Gambling and Other Compulsive 
Behaviors” will be analyzed as an AESI.  
8.8.6  Potential Serious Hepatotoxicity  
For a subject who experiences an elevation in AST or ALT  that is  ≥ 3 times the ULN , a 
total bilirubin level should also be evaluated. If the total bilirubin is ≥  2 times the ULN, 
complete an IRE form with all values listed and also report as an AE in eSour ce. 
8.8.7  Procedure for Breaking the Blind 
This trial will not use blinding procedures. 
8.8.8  Follow -up of Adverse Events  
8.8.8.1  Follow -up of Nonserious Adverse Events  
Nonserious AEs that are identified at any time during the trial must be recorded on the 
AE page in eSource with the current status (ongoing or resolved/recovered) noted. All nonserious events (that are not IREs) that are ongoing at the last scheduled contact will 
be recorded as ongoing in eSource. For any AE having been identified throughout the 
trial, during analysis, additional relevant medical history information may be requested by the sponsor to further ascertain causality (including, but not limited to, information such as risk -related behavior, family history and occupation). 
Protocol 331-201-00195  
54 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  8.8.8.2  Follow -up of Immediately Reportable Events 
This trial requires that subjects be actively monitored for IREs up to 21 (±  3) days after 
the last dose of IMP is administered.  
Immediately reportable events that are identified or ongoing at the last scheduled contact 
must b e recorded as such on the AE page in eSource and the IRE form. If updated 
information (eg, resolved status) on IRE status becomes available after a subject’s last scheduled contact (up to last in- clinic visit for the entire trial), this must be reported to  the 
sponsor and recorded on the AE page in eSource and the IRE form, according to the 
appropriate reporting procedures described in Section  8.8.3. 
It is expected that the investigator will provide or arrange appropriate supportive care for the subject and will provide prompt updates on the subject’s status to the sponsor. The 
investigator will follow IREs until the even ts are:  
• resolved, 
• stabilized,  
• the subject is lost to follow -up, or 
• has died. 
 
Resolution means that the subject has returned to the baseline state of health and 
stabilized means that the investigator does not expect any further improvement or 
worsening of the subject’s condition. The investigator will continue to report any 
significant follow -up information to the sponsor up to the point the event has resolved or 
stabilized, or the subject is lost to follow -up, or has died. 
Refer to Section  10.3 for additional information regarding the follow-up period for 
subjects that become pregnant or for pregnant partners of male subjects. 
8.8.8.3  Follow -up and Reporting of Immediately Reportable Events 
Occurring After Last Scheduled Contact  
Any new IREs reported to the investigator which occur after the last scheduled contact  
and are determined by the investigator to be reasonably associated with the use of the 
IMP, should be reported to the sponsor according to the procedures outlined in 
Section  8.8.3. This may include IREs that are captured on follow-up telephone contact or 
at any other time point after the defined trial period and continue to report any significant follow-up information to the sponsor until the events are resolved or stabilized, or the 
subject is lost to follow -up or has died. 
Protocol 331-201-00195 
55 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 8.9 Treatment of Overdose 
For treatment of overdose, please refer to the current IB section for overdose.10 
8.10 Subject Assessment Recording 
8.11 Other Assessments 
Not applicable. CCI
Protocol 331-201-00195 
56 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 9 Statistical Considerations 
9.1 Sample Size 
The sample size is not based on statistical power considerations but on the number of 
subjects rolling over from the lead-in trials . The trial population will be derived from 
eligible subjects who completed the previous  double-blind brexpiprazole BPD trials. The 
number of eligible subjects will be limited by the number of subjects enrolled into the 
double-blind trials. 
9.2 Datasets for Analysis 
The following datasets are defined for this trial: 
x Enrolled Sample, which comprises all subjects who sign an ICF for the trial and are 
enrolled into the trial. 
x Safety Sample, which comprise s all subjects who will receive at least 1 dose of IMP. 
 
9.3 Handling of Missing Data for Primary and Secondary Endpoint 
Analysis 
In order to assess the sensitivity of results due to missing data, 2 types of analyses will be 
performed: last observation carried forward (LOCF) and observed cases (OC). The OC 
dataset will consist of the actual observations recorded at each visit. The LOCF dataset will include data recorded at a scheduled visit, ie, all OC data, or, if no observation is recorded at that visit, data will be carried forward from the previously scheduled visit. 
Baseline data will not be carried forward to impute missing values for the LOCF dataset. 
The OC dataset will be used for analyses at each trial visit and the LOCF dataset will be used for analyses at the last visit. 
9.4 Statistical Analyses 
9.4.1 Efficacy Analyses 
. 
9.4.2 Safety Analysis 
The primary safety endpoint analysis is the frequency and severity of AEs in the 
open-label treatment phase. In general, baseline of a safety  variable is defined as the last 
observation of the variable before taking the first dose of IMP, unless specified 
otherwise. CCI
Protocol 331-201-00195  
57 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  9.4.2.1  Adverse Events  
All AEs will be coded by system organ class and Medical Dictionary for Regulatory 
Activities preferred term. The incidence of the following events will be summarized by 
the prior treatment group: 
• Treatment -emergent AEs (TEAEs)  
• TEAEs by severity  
• TEAEs potentially causally related to the I MP 
• TEAEs with an outcome of death 
• Serious TEAEs  
• TEAEs leading to discontinuation of the IMP  
• AESI  
 
A TEAE is defined as an AE that starts after the first dose of IMP or an AE that is 
reported at baseline and increases in intensity or becomes serious or IMP-related or 
results in death, discontinuation, interruption or reduction of IMP. Information about new onset or exacerbation of “Pathological Gambling and Other Compulsive Behaviors” will 
be collected and analyzed as an AE of special interest.  
9.4.2.2  Clinical Lab oratory Data 
Summary statistics for changes from baseline in the routine clinical laboratory 
measurements will be provided. In addition, the incidence of potentially clinically relevant values identified using prospectively defined in the statistical analy sis plan 
(SAP) criteria for laboratory tests will be summarized.  
9.4.2.3  Physical Examination and Vital Signs Data 
Physical examination findings will be listed by subject. Potentially clinically relevant results in vital signs and body weight will also be summariz ed. 
Summary statistics for change from baseline in vital signs, body weight, and waist circumference will be provided. 
9.4.2.4  Electrocardiogram Data 
Mean change from baseline will be summarized by visit.  
The incidence of clinically relevant changes will be calculated for ECG parameters and 
summarized by visit.  
Protocol 331-201-00195  
58 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  For the analysis of QT and corrected QT interval ( QTc) data from 3 consecutive 
complexes (representing 3 consecutive heart beats) will be measured to determine 
average values. The following QT correcti ons will be used: 
1) QTcB is the length of the QT interval corrected for heart rate using Bazett’s formula: 
QTcB=QT/(RR)0.5, and 
2) QTcF is the length of the QT interval corrected for heart rate using Fridericia ’s 
formula:  
QTcF=QT/(RR)0.33 
3) QTcN is the length of the QT interval corrected for heart rate using the Food and Drug 
Administration ( FDA ) Neuropharm Division formula:  
QTcN =QT/(RR)0.37 
Results will be summarized by visit.  
9.4.2.5  Other Safety Data  
Change from baseline in scores for EPS (eg, SAS, AIMS, and BARS) will be evaluated using descriptive statistics. The analyses will be based on the OC and LOCF datasets of 
the Safety Sample. 
Suicidality (eg, C- SSRS) will be summarized by the prior treatment group by descriptive 
statistics. Details will be described in SAP.  
9.4.3  Other Analyses  
9.4.3.1  Analysis of Demographic and Baseline Characteristics  
Baseline demographic characteristics including age, race, ethnicity, sex , weight, height, 
and body mass index will be summarized by descriptive statistics (frequency, mean, 
median, standard deviation, maximum, minimum, and percentage when applicable). 
9.4.3.2  Pharmacokinetic Analysis  
No PK analysis is planned. 
9.4.3.3  Phar macodynamic Analysis  
No pharmacodynamic ( PD) analysis is planned. 
9.4.3.4  Pharmacokinetic/Pharmacodynamic Analysis  
No PK/PD analysis is planned. 
Protocol 331-201-00195 
59 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 9.4.3.5 Pharmacogenomic Analysis 
No pharmacogenomic analysis is planned. 
9.5 Interim Analysis and Adaptive Design 
No interim analysis or adaptive design are planned. 
9.5.1 Data Monitoring Committee 
Not applicable. CCI
Protocol 331-201-00195  
60 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  10 Supporting Documentation and Operational Considerations  
10.1 Appendix 1: Regulatory, Ethical, and Trial Oversight 
Considerations  
10.1.1  Ethics and Responsibility  
This trial must be conducted in compliance with the protocol, FDA regulations, 
International Council for Harmonisation ( ICH) GCP: Consolidated Guideline (E6[R2]), 
international ethical principles derived from the Declaration of Helsinki and Council for 
International Organizations of Medical Science guidelines, and applicable local laws and 
regulations. Each trial site will seek approval/favorable opinion by an IR B or IEC 
according to regional requirements, and the investigator will provide that documentation to the sponsor. The IRB/IEC will evaluate the ethical, scientific and medical 
appropriateness of the trial. Further, in preparing and handling eSource, the investigator, 
subinvestigator and their staff will take measures to ensure adequate care in protecting subject privacy. To this end, a subject ID will be used to identify each subject. 
Financial aspects, subject insurance and the publication policy for the t rial will be 
documented in the agreement between the sponsor and the investigator. 
10.1.2  Informed Consent  
Informed consent will be freely obtained from all subjects (or their guardian or legally 
acceptable representative, as applicable for local laws). The ICF w ill be approved by the 
same IRB/IEC that approves this protocol. 
Each ICF will comply with the ICH GCP: Consolidated Guideline E6 (R2)
27 and local 
regulatory requirements. The investigator will ensure that the sponsor reviews and 
authorizes any written site -specific ICF used in the trial before submission to the 
IRB/IEC. In support of the site’s standard process for administering informed consent, this trial will also allow for electronic informed consent (eICF) as a tool within applicable regions and trial sites. The eICF utilizes the IRB /IEC -approved site- specific ICF to offer 
subjects an enhanced platform to review and understand their rights as a research subject 
as well as required trial procedures. When possibl e, trial sites will have subjects review 
and sign the eICF prior to starting any trial procedures; however if local regulations does 
not allow for use of the electronic format, subjects may continue in the trial utilizing the standard paper and wet ink signature process. 
Protocol 331-201-00195  
61 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Investigators may discuss trial availability and the possibility for entry with a potential 
subject without first obtaining consent. However, informed consent must be obtained and 
documented before initiation of any procedures that are performed solely for the purpose 
of determining eligibility for this trial, including withdrawal from current medication(s).  
Potential subjects are free to refuse entry into the trial, or withdraw from the trial at any time, without justification, and there w ill be no consequences to their further care.  
Prospective trial subjects will be provided with controlled access to the eICF application by trial site staff. When the trial site staff and the subject agree that the subject has enough information to make an informed decision to participate, the subject will electronically sign in the eICF application and an electronic date and timestamp will be 
applied to the signature. The subject will be given a printed, signed copy of the ICF. Any 
other parties required by the IRB/IEC (trial site staff, witnesses, or legally authorized representative) are also required to sign electronically and these signatures will be stored with the eICF in accordance with the ICH GCP Guideline and local regulatory 
requirements/guidelin es. These signatures cannot be altered, removed, or copied. 
Once appropriate essential information has been provided and fully explained in 
layman’s language to the subject by the investigator (or a qualified designee), and it has been documented that the subject has had the opportunity to ask questions, the 
IRB/IEC -approved written ICF will be signed and dated by both the subject and the 
person obtaining consent (investigator or designee), as well as by any other parties 
required by the IRB/IEC . The subject will receive a copy of the signed ICF; the original 
shall be kept on file by the investigator. 
Subjects may be asked to sign additional ICFs if the protocol is amended and the changes 
to the protocol results in additional information that needs to be provided to the subjects, so that they can make a knowledgeable and voluntary decision on continued trial 
participation. Female partners of male subjects who become pregnant during the course 
of the trial may be asked to sign additional ICFs in order to colle ct additional information 
regarding the nonsubject partner and fetus. 
10.1.3  Confidentiality  
All information generated in this trial will be considered confidential and will not be 
disclosed to anyone not directly concerned with the trial without the sponsor’s pr ior 
written permission. Subject confidentiality requirements of the region(s) where the trial is 
conducted will be met. However, authorized regulatory officials and sponsor personnel (or their representatives) may be allowed full access to inspect and copy the records, 
consistent with local requirements. All IMPs, subject bodily fluids, and/or other materials 
Protocol 331-201-00195  
62 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  collected shall be used solely in accordance with this protocol, unless otherwise agreed to 
in writing by the sponsor. 
Subjects will be identified only by unique subject ID in eSource . If further subject 
identification is required, subjects’ full names may be made known to a regulatory 
agency or other authorized officials if necessary, subject to local regulations. 
10.1.4  Quality Control and Quality Assurance  
10.1.4.1  Monitoring  
The sponsor has ethical, legal, and scientific obligations to follow this trial in accordance 
with established research principles, the ICH GCP: Consolidated Guideline (E6[R2]), and 
applicable regulatory requirements and local laws. As part of a concerted effort to fulfill 
these obligations (maintain current personal knowledge of the progress of the trial), the sponsor’ s monitors will visit the site during the trial, as well as communicate frequently 
via telephone, e- mail, and written communications. In addition, all investigators and trial 
site personnel will undergo initial and ongoing training for this particular trial, and this training will be clearly documented.  
10.1.4.2  Auditing 
The sponsor’s Quality Assurance Unit (or representative) may conduct tr ial site audits. 
Audits will include, but are not limited to, IMP supply, presence of required documents, the informed consent process, and a review of eSource with source documents, as applicable. The investigator agrees to participate with audits.  
Regulatory authorities may inspect the investigator site during or after the trial. The 
investigator will cooperate with such inspections and will contact the sponsor 
immediately if such an inspection occurs. 
10.1.5  Protocol Deviations  
In the event of a significant deviation from the protocol due to an emergency, accident, or 
mistake (eg , violation of informed consent process, IMP dispensing or subject dosing 
error, subject enrolled in violation of eligibility criteria or concomitant medication 
criteria),  the investigator or designee will contact the sponsor or designee at the earliest 
possible time by telephone or via e-mail. The investigator and sponsor (or designee) will 
come as quickly as possible to a joint decision regarding the subject’s continuation in the 
trial. This decision will be documented by the investigator and the sponsor (or designee) and reviewed by the site monitor. 
Any major protocol deviation will be recorded in eSource along with the start date and 
details of the deviation. 
Protocol 331-201-00195  
63 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  10.1.6  Records Management  
10.1.6.1  Source Documents  
Source documents are defined as the results of original observations and activities of a 
clinical investigation. Source documents will include but are not limited to medical 
records, electronic data, screening /baseline  logs, and r ecorded data from automated 
instruments. All source documents pertaining to this trial will be maintained by the 
investigators and made available for direct inspection by authorized persons. 
Investigator(s)/institution(s) will permit trial-related monitoring, audits, IRB/IEC review , 
and regulatory inspection(s) by providing direct access to source data/documents by 
authorized persons as defined in the ICF. In all cases, subject confidentiality must be maintained in accordance with local regulatory requirements. 
10.1.6.2  Data Collection  
During each subject’s visit to the site or remote visit, an investigator or their designee 
participating in the trial will record information to document all significant observations. 
At a minimum, these notes will contain: 
• Documentati on of the informed consent process, including any revised consents; 
• Documentation of the investigator’s decision to enroll the subject into the trial, the 
review of all inclusion/exclusion criteria prior to IMP administration, and confirmation of the subje ct’s actual participation in the trial; 
• The date of the visit and the corresponding Visit or Day in the trial schedule; 
• General subject status remarks, including any significant medical findings. The severity, frequency, duration, action taken, and outcome of any AEs and the investigator’s assessment of relationship to IMP must also be recorded; 
• Any changes in concomitant medications or dosages; 
• A general reference to the procedures completed;  
• The signature (or initials) and date of the investigator (or designee) who made an entry in the medical record.  
 In addition, any contact with the subject via telephone or other means that provides 
significant clinical information will also be documented in the progress notes as 
described above.  
Source documents and s ource data will be captured electronically (where permitted by 
local regulation) in this trial and will meet the same fundamental elements of data quality 
(eg, attributable, legible, contemporaneous, original, and accurate) as paper records. 
These data wil l be collected into a system that is fully validated according to 21 Code of 
Protocol 331-201-00195  
64 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Federal Regulations Part  11. Changes to the data will be captured by an automatic audit 
trail. 
Designated trial site staff will not be given access to the electronic source system  until 
they have been appropriately trained. Information to be originally captured and reviewed 
electronically shall include details of the subject visit and the protocol required assessments performed as a part of these visits, medical history, AEs, and concomitant 
medications. Because this trial is using an electronic source record as the original point of 
data capture, there is no additional data entry step for the trial site for data collected directly into the application, rather, the electronic source record directly populates the trial database.  
Some data may be captured via paper and then entered into the eSource system. These a
nd any other data treated in this manner will be source data verified per the monitoring 
plan and the location of the source data (ie, eSource, paper, or a local electronic system) will be documented before the trial start. Any changes to information in paper source 
documents will be initialed and dated on the day the change is made by a trial site staff 
member authorized to make the change. Changes will be made by striking a single line 
through erroneous data (so as not to obliterate the original data), and clearly entering the correct data (eg, wrong data right data). If the reason for the change is not apparent, a 
brief explanation for the change will be written in the source documentation by the investigator or their designee. 
Another exception will be safety laboratory [or central ECG data], where the official 
s
ource documentation will be considered the report issued by the analyzing laboratory.  
Remote monitoring of the original electronic source records will take place; however, 
on-site monitoring inspections will continue to take place in order to review data entry of source documentation directly captured on paper and transcribed into the system, to 
ensure protocol adherence, to assess trial site operational capabilities and to perform 
other monitoring activities that cannot be performed remotely. 
At the end of the trial, the investigator must certify that the data entered into the eSource 
application are complete and accurate. After database lock, the investigator will receive 
an electronic copy of the subject data.  
10.1.6.3  File Management at the Trial Site  
The investigator will ensure that the trial site file is maintained  in accordance with 
Section 8 of the ICH GCP: Consolidated Guideline (E6[R2]) and as required by 
applicable local regulations. The investigator/institution will take measures to prevent 
accidental or premature destruction of these documents.  
Protocol 331-201-00195  
65 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  10.1.6.4  Records Retent ion at the Trial Site  
Regulatory requirements for the archival of records for this trial necessitate that 
participating investigators maintain detailed clinical data for the longest of the following 
3 periods: 
• A period of at least 2 years after the date on  which approval to market the drug is 
obtained (or if IMP development is discontinued, the date regulatory authorities were 
notified of discontinuation); OR 
• A period of at least 3 years after the sponsor notifies the investigator that the final 
report has been filed with regulatory authorities. 
• Longer, region- specific storage requirements, if applicable.  
 
The investigator must not dispose of any records relevant to this trial without either 
(1) written permission from the sponsor or (2) provision of an opportunity for sponsor to 
collect such records. The investigator will be responsible to maintain adequate and accurate electronic or hard copy source documents of all observations and data generated during this trial including any data clarification forms re ceived from the sponsor. Such 
documentation is subject to inspection by the sponsor and relevant regulatory authorities. If the investigator withdraws from the trial (eg, due to relocation or retirement), all trial-related records should be transferred to a mutually agreed -upon designee within a 
sponsor-specified timeframe. Notice of such transfer will be given to the sponsor in 
writing.  
10.1.6.5  Publication Authorship Requirements  
Authorship for any Otsuka-sponsored publications resulting from the conduct of this t rial 
will be based on International Committee of Medical Journal Editors (ICMJE) authorship 
criteria (http://www.icmje.org/recommendations). According to ICMJE guidelines, one 
may be considered an author only if the following criteria are met: 
1) Substantial contributions to the conception or design of the work; or the 
acquisition, analysis, or interpretation of data for the work; AND 
2) Drafting the work or revising it critically for important intellectual content; AND  
3) Final approval of the version to be published; AND 
4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. 
 All authors must meet the above criteria, and all who qualify for authorship based on the 
above criteria should be listed as authors. 
Protocol 331-201-00195  
66 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Investigators or other trial subjects who do not qualify for authorship may be 
acknowledged in publications resulting from the trial. By agreeing to participate in the 
trial, inves tigators or other trial subjects consent to such acknowledgement in any 
publications resulting from its conduct. 
Protocol 331-201-00195  
67 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  10.2 Appendix 2: Clinical Laboratory Tests  
The tests detailed in Table 10.2-1 will be performed. 
Table 10.2-1 Clinical Laboratory Assessments  
Hematology:  
HbA1c  
Hemoglobin  
Hematocrit  
MCH  
MCHC  
MCV  
Platelet count  
RBC count  
RBC morphology  
RDW  
WBC count with differential   
Urinalysis:  
Specimen Appearance  
Color  
Occult Blood  
Glucose  
Microscopic analysis, WBC/RBC counts per high 
powered field  
pH 
Protein  
Specific Gravity  
Ketones  
 
Urine Drug Screens:  
Amphetamines/MDMA  
Barbiturates  
Benzodiazepines  
Cannabinoids  
Cocaine 
Methadone  
Opiates  
Phencyclidine  
Propoxyphene  
 
Drug and A l cohol Screening : 
Blood alcohol  Serum Chemistry:  
ALP  
ALT  
AST  
Bilirubin, total  
BUN  
Calcium  
Cholesterol (total, LDL, and HDL)  
CPK  
Creatinine  
GGT  
Glucose  
LDH Magnesium  
Potassium  
Prolactin  
Protein, total  
Sodium  
Triglycerides  
Uric acid  
 
Additional Tests: 
Urine and serum pregnancy for FOCBPa 
 
ALP = alkaline phosphatase; BUN  = blood urea nitrogen;  GGT = gamma glutamyl transferase;  
HDL = high -density lipoprotein; LDH  = lactic dehydrogenase; LDL = low -density lipoprotein; 
MCH  = mean corpuscular hemoglobin;  MCHC = mean corpuscular hemoglobin concentration; 
MCV  = mean corpuscular volume;  MDMA = methylenedioxymethamphetamine; RBC  = red blood 
cell; RDW = red cell distribution width; WBC = white blood cell.  
aAll positive urine pregnancy test results must be confirmed by a serum test. Subjects with a positive 
serum pregnancy test result at screening /baseline  must not be enrolled and subjects with a pos itive 
serum pregnancy test result during the trial must discontinue treatment and be withdrawn from the 
trial. 
Protocol 331-201-00195  
68 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  10.3 Appendix 3: Contraceptive Guidance and Collection of Pregnancy 
Information 
Females of childbearing potential are females whose menstruation has s tarted and who 
are not documented as sterile (eg, have had a bilateral oophorectomy, or hysterectomy, or 
who have been postmenopausal for at least 12 months). 
For males and FOCBP, who are sexually active, there must be a documented agreement 
that the subje ct and their partner will take effective measures (ie,  2 different approved 
methods of birth control or remains abstinent) to prevent pregnancy during the course of 
the trial and for 30 days after the last dose of IMP. Unless the subject is sterile (ie, 
females who have had a bilateral oophorectomy, have had a hysterectomy, or have been 
postmenopausal for at least 12 consecutive months; or males who have had a bilateral orchiectomy) or remains abstinent during the trial and for 30 days after the last dose of 
IMP, 2 of the following approved methods of birth control must be used: vasectomy, 
tubal ligation, intrauterine device, birth control pills, birth control implant, birth control depot injection, condom with spermicide, sponge with spermicide, or occlusive cap (vaginal diaphragm or cervical/vault cap) with spermicide. Any single method of birth 
control, including vasectomy and tubal ligation, may fail, leading to pregnancy. The 
contraceptive method will be documented in eSource. Abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the trial treatments. The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the subject. 
Consensual sexual activity that cannot biologically result in pregnancy may not be subject to required birth control methods, following discussion with the medical monitor. 
Male subjects must also agree not to donate sperm from trial screeni ng/baseline  through 
30 days after the last dose of IMP.  
Before enrolling males and females in this clinical trial, investigators must review the 
below information about trial participation as part of the ICF process. The topics should 
generally include: 
• General information  
• Informed consent form 
• Pregnancy prevention information 
• Drug interactions with hormonal contraceptives 
• Contraceptives in current use 
• Follow-up of a reported pregnancy 
 
Protocol 331-201-00195  
69 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Before trial enrollment, males and FOCBP must be advised of the importance of avoiding 
pregnancy during trial participation and the potential risk factors for an unintentional 
pregnancy. Subjects must sign the ICF confirming that the above-mentioned risk factors 
and the consequences were discussed.  
A urine or serum pregnancy test for human chorionic gonadotropin will be performed at screening /baseline  and at each check -in to the inpatient facility on all FOCBP. If a urine 
test is performed and is positive, the investigator will follow -up with a confirmatory 
serum test.  
During the trial, all FOCBP should be instructed to contact the investigator immediately if they suspect they might be pregnant (eg, missed or late menstrual cycle). Male subjects 
must be instructed to contact the investigator immediately, during the trial, if their partner 
suspects that they might be pregnant (eg, missed or late menstrual cycle). 
If a subject is suspected to be pregnant before she receives IMP, the IMP administration 
must be withheld until the results of serum pregnancy tests are available . If the pregnancy 
is confirmed, the subject must not receive the IMP and must not be enrolled in the trial. If pregnancy is suspected while the subject is taking IMP, the IMP must be withheld immediately (if reasonable, taking into consideration any potential withdrawal risks) until the result of the pregnancy test is known. If pregnancy is confirmed, the IMP will be 
permanently discontinued in an appropriate manner (eg, dose tapering if necessary for 
subject safety) and the subject will be withdrawn from the trial. Exceptions to trial discontinuation may be considered for life-threatening conditions only after consultations 
with the IRE contact (see the title page of this protocol for contact information). 
The investigator must immediately notify the sponsor (within 24 hours) of any pregnancy 
associated with IMP exposure during the trial and for at least 30 days after the last dose of IMP, and record the event on the IRE form and forward it to the sponsor. The sponsor 
will forward the Pregnancy Surveillance Form(s) to the investigator for monitoring the 
outcome of the pregnancy. 
Protocol required procedures for trial discontinuation and follow-up must be performed 
on the subject unless contraindicated by pregnancy (eg, x-ray studies). Other appropriate 
pregnancy follow -up procedures should be considered if indicated. In addition, the 
investigator must report to the sponsor, on the Pregnancy Surveillance Form(s), 
follow-up information regarding the course of the pregnancy, including perinatal and neonatal outcome. Infants will be followed for a minimum of 6 months from the date of 
birth.  
Protocol 331-201-00195 
70 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 10.4 Appendix 4: Abbreviations 
Abbreviation Definition 
5-HT Serotonin 
AAD Agitation in Alzheimer’s dementia ADHD Attention-deficit/ hyperactivity disorder 
ADT Antidepressant therapy AE Adverse event AESI Adverse event of special interest AIMS Abnormal Involuntary Movement Scale ALP Alkaline phosphatase ALT (SGPT) Alanine aminotransferase (serum glutamic-pyruvic transaminase) 
AST (SGOT) Aspartate aminotransfera se (serum glutamic-oxaloacetic 
transaminase) 
BARS Barnes Akathisia Rating Scale BPD Borderline personality disorder bpm Beats per minute 
BUN Blood urea nitrogen 
  
  
  
COVID-19 Coronavirus disease of 2019 
CPK Creatine phosphatase 
C-SSRS Columbia-Suicide Severity Rating Scale 
CYP Cytochrome P450 D Dopamine DBP Diastolic blood pressure DSM-IV Diagnostic and Statistical Manua l of Mental Disorders, 4th edition 
ECG Electrocardiogram eICF Electronic informed consent EPS Extrapyramidal symptoms ET Early termination FDA Food and Drug Administration FOCBP Females of childbearing potential GCP Good Clinical Practice 
GGT Gamma glutamyl transferase 
  
HbA1c Glycosylated hemoglobin 
HDL High-density lipoprotein IB Investigator’s Brochure ICF Informed consent form ICH International Council for Harmonisation ICMJE International Committee of Medical Journal Editors ID Identifier IEC Independent ethics committee IMP Investigationa l medicinal product 
IND Investigational New Drug CCICCI
CCI
Protocol 331-201-00195 
71 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 Abbreviation Definition 
IRB Institutional review board 
IRE Immediately reportable event 
Ki Inhibition constant 
LDH Lactic dehydrogenase 
LDL Low-density lipoprotein LOCF Last observation carried forward MCH Mean corpuscular hemoglobin MCHC Mean corpuscular hemoglobin concentration 
MCV Mean corpuscular volume MDD Major depressive disorder MDMA Methylenedioxymethamphetamine OC Observed cases 
PD Pharmacodynamic 
 
  
PK Pharmacokinetic 
PQC Product quality  complaint 
PTSD Post-traumatic stress disorder QTc Corrected QT interval QTcB QT interval corrected for heart rate using Bazett’s formula QTcF QT interval corrected for heart rate using Fridericia’s formula QTcN QT interval corrected for heart rate using the Food and Drug 
Administration Neuropharm Division formula 
RBC Red blood cell RDW Red cell distribution width SAE Serious adverse event SAP Statistical analysis plan SAS Simpson Angus Scale SBP Systolic blood pressure SYE Subject years of exposure TEAE Treatment-emergent adverse event ULN Upper limit of normal US  United States  
WBC White blood cell 
   
  CCICCI
CCI
Protocol 331-201-00195  
72 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  10.5 Appendix 5: Criteria for Identifying Laboratory Values of Potential 
Clinical Relevance  
Laboratory Tests  Criteria  
Chemistry   
AST (SGOT)  ≥ 3 x ULN 
ALT (SGPT)  ≥ 3 x ULN 
Alkaline phosphatase  ≥ 3 x ULN 
Lactate dehydrogenase  ≥ 3 x ULN 
Blood urea nitrogen  ≥ 30 mg/dL  
Creatinine  ≥ 2.0 mg/dL  
Uric acid   
Men ≥ 10.5 mg/dL  
Women  ≥ 8.5 mg/dL  
Bilirubin (total)  ≥ 2.0 mg/dL  
Creatine phosphokinase  > 3 x ULN  
Prolactin  > ULN  
Hematology   
Hematocrit   
Men ≤ 37 % and decrease of ≥ 3 percentage points from baseline  
Women  ≤ 32 % and decrease of ≥ 3 percentage points from baseline  
Hemoglobin   
Men ≤ 11.5 g/dL  
Women  ≤ 9.5 g/dL  
WBC count  ≤ 2,800 mm3 or ≥ 16,000 mm3  
Eosinophils  ≥ 10% 
Neutrophils  ≤ 15% 
Absolute neutrophil count  ≤ 1,500/mm3 
Platelet count  ≤ 75,000/mm3 or ≥ 700,000/mm3 
Urinalysis   
Protein  Increase of ≥ 2 units 
Glucose  Increase of ≥ 2 units  
Casts  Increase of ≥ 2 units  
Additional Criteria   
Chloride  ≤ 90 mEq/L or ≥ 118 mEq/L  
Potassium  ≤ 2.5 mEq/L or ≥ 6.5 mEq/L  
Sodium  ≤ 126 mEq/L or ≥ 156 mEq/L  
Calcium  ≤ 8.2 mg/dL or ≥ 12 mg/dL  
Glucose   
Fasting  ≥ 100 mg/dL  
Nonfasting  ≥ 200 mg/dL  
Total cholesterol, fasting  ≥ 240 mg/dL  
LDL cholesterol, fasting  ≥ 160 mg/dL  
HDL cholesterol, fasting   
Men < 40 mg/dL  
Women  < 50 mg/dL  
Triglycerides, fasting  ≥ 150 mg/dL  
Protocol 331-201-00195  
73 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  10.6 Appendix 6 : Criteria for Identifying Vital Signs of Potential Clinical 
Relevance  
 
Variable  Criterion Valuea Change Relative to 
Baselinea 
Heart rateb > 100 bpm  
< 50 bpm  ≥ 10 bpm increase  
≥ 10 bpm decrease  
Systolic blood pressureb ≥ 140 mmHg Supine  
< 90 mmHg  ≥ 20 mmHg increase  
≥ 20 mmHg decrease  
Diastolic blood pressureb ≥ 90 mmHg Supine  
< 60 mmHg  ≥ 10 mmHg increase  
≥ 10 mmHg decrease  
Orthostatic hypotension  ≥ 30 mmHg decrease in systolic blood 
pressure and/or a decrease of ≥  20 mmHg 
in diastolic blood pressure after at least 
3 minutes of standing compared to the 
previous supine blood pressure.  Not applicable  
(baseline status not 
considered)  
Orthostatic tachycardia  ≥ 25 bpm increase in heart rate from 
supine to standing  Not applicable  
(baseline status n ot 
considered)  
Weight  − ≥ 7% increase  
≥ 7% decrease  
bpm = beats per minute.  
aIn order to be identified as potentially clinically relevant, an on -treatment value must meet the 
“Criterion Value” and also represent a change from the subject’s baseline value of at least the 
magnitude shown in the “Change Relative to Baseline” column.  
bAs defined in “Supplementary Suggestions for Preparing an Integrated Summary of Safety Information in 
an Original New Drug Application Submission and for Organizing Information in Periodic Safety 
Updates,” FDA Division of Neuropharmacological Drug Products draft (2/27/87).  
Protocol 331-201-00195  
74 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  10.7 Appendix 7 : Criteria for Identifying ECG Measurements of 
Potential Clinical Relevance  
Variable  Criterion Valuea Change Relative to 
Baselinea 
Rate    
Tachycardia  ≥ 120 bpm  increase of  ≥ 15 bpm  
Bradycardia  ≤ 50 bpm  decrease of ≥ 15 bpm  
Rhythm    
Sinus tachycardiab ≥ 120 bpm  increase of ≥  15 bpm  
Sinus bradycardiac ≤ 50 bpm  decrease of ≥  15 bpm  
Supraventricular premature beat  all not present → present  
Ventricular premature beat  all not present → present  
Supraventricular tachycardia  all not present → present  
Ventricular tachycardia  all not present → present  
Atrial fibrillation  all not present → present  
Atrial flutter  all not present → present  
Conduction    
1 atrioventricular block  PR ≥ 200 msec  increase of ≥ 50 msec  
2 atrioventricular block  all not present → present  
3 atrioventricular block  all not present → present  
Left bundle -branch block  all not present → present  
Right bundle -branch block  all not present → present  
Pre-excitation syndrome  all not present → present  
Other intraventricular conduction blockd QRS ≥ 120 msec  increase of ≥  20 msec  
Infarction    
Acute or subacute  all not present → present  
Old all not present → present  
  ≥ 12 weeks post trial entry  
ST/T Morphological    
Myocardial ischemia  all not present → present  
Symmetrical T -wave inversion  all not present → present  
Increase in QTc  QTcF >  450 msec  
(males)  
QTcF >  470 msec  
(females)   
QTc = corrected QT interval ; QTcF = QT interval corrected for heart rate using Fridericia’s formula . 
aIn order to be identified as potentially clinically relevant, an on -treatment value must meet the 
“Criterion Value” and also represent a change from the subject’s baseline value of at least the 
magnitude shown in the “Change Relative to Baseline” column.  
bNo current diagnosis of supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, atrial 
flutter, or other rhythm abnormalit y. 
cNo current diagnosis of atrial fibrillation, atrial flutter, or other rhythm abnormality.  
dNo current diagnosis of left bundle branch block or right bundle branch block.  
 
Protocol 331-201-00195  
75 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  10.8 Appendix 8: Protocol Amendments  
The investigator will not make any changes to this protocol without the sponsor’s prior 
written consent and subsequent approval/favorable opinion by the IRB/IEC. Any 
permanent change to the protocol, whether an overall change or a change for specific trial 
site(s), must be handled as a protocol amendment. Any amendment will be written by the sponsor. Each amendment will be submitted to the IRB/IEC, as required by local regulations. Except for “administrative” or “nonsubstantial” amendments, investigators 
will wait for IRB/IEC approval/favorable opinion of the amended protocol before 
implementing the change(s). Administrative amendments are defined as having no effect on the safety of subjects, conduct or management of the trial, trial design, or the quality or safety of IMP(s) used in the trial. A protocol change intended to eliminate an apparent 
immediate hazard to subjects should be implemented immediately after agreement by the 
sponsor and investigator, followed by IRB/IEC notification within local applicable timelines. The s ponsor will submit protocol amendments to the applicable regulatory 
agencies within local applicable timelines.  
When the IRB/IEC, investigators, and/or the sponsor conclude that the protocol amendment substantially alters the trial design and/or increases the potential risk to the subject, the currently approved written ICF will require similar modification. In such cases, after approval/favorable opinion of the new ICF by the IRB/IEC, repeat written 
informed consent will be obtained from subjects enrolled in the trial before expecting 
continued participation and before the amendment- specified changes in the trial are 
implemented.  
Protocol 331-201-00195  
76 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  10.8.1  Protocol Amendment(s)/Administrative Change(s)  
10.8.1.1  Protocol Amendment 1  
 
Amendment 1 Approval Date:  01 Ju l 2020 
 PURPOSE:  
The purpose of this protocol amendment is to introduce an addendum for COVID -19 for 
any protocol-specified activities that are not able to be performed or cannot be performed 
due to COVID-19 considerations. Refer to the COVID-19 Addendum (dated 01 Ju l 2020) 
for the a ppropriate measures to be followed. Additional administrative changes were 
made to the protocol and are documented below. Finally, minor editorial revisions were made for consistency with Otsuka style and for internal consistency. 
 
BACKGROUND:  
These changes to clinical trial protocol 331-201-00195, originally issued on 
21 Aug  2019, were made to introduce a COVID-19 addendum. In addition, 
administrative changes were incorporated as described in the protocol clarification 
memos (dated 20 Nov  2019 and 12 Feb  2020). 
 
MODIFICATIONS TO PROTOCOL:  
General Revisions:  
• Clarified in the trial design sections, for consistency with the schedule of assessments, that an optional telephone call or other form of communication will be made with the subject approximately 1 week (± 2 days) after the visit (eg, at Weeks 3, 5, 7, 9, and 11) to check on status. 
• Modified exclusion criterion #1 to indi cate that consensual sexual activity that 
cannot biologically result in pregnancy may not be subject to required birth control methods (following discussion with the medical monitor). 
• Added to exclusion criterion #6 that if the major protocol deviation is due to COVID-19, eligibility for the subject to continue can be discussed with medical monitor. 
• Added that rescreening of subjects is not permitted. 
• For medications prohibited during the trial, added an exception for gabapentin when used to treat anxiety or pain  (after discussion with the medical monitor ). 
• Added trazodone to the list of medications prohibited during the trial (unless it is being used for sleep management, in which case further discussion with the medical monitor is required) . 
Protocol 331-201-00195 
77 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 x  
x Added that the investigator (or their designee participating in the trial) will record 
information to document all significant obser vations at remote visits (in addition 
to site visits). 
x Incorporated the following items from the protocol clarification memos: 
 Revised the following text: “Note: as sessments from the last scheduled 
treatment visit in the previous double-bli nd trial that are going to be used as 
the baseline measures for Trial 331-201-00195 will not need to be repeated if 
the subject enters Trial 331-201-00195 within 3 days  
 Revised the following text: “Weight shoul d be recorded before a subject’s 
meal and at approximately the same time at each visit  
 
 Added a definition of abstinence: “Abs tinence is defined as refraining from 
heterosexual intercourse dur ing the entire period of risk associated with the 
trial treatments. The relia bility of sexual abstinence should be evaluated in 
relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.” 
 Removed insulin and added HbA1c to  the list of laboratory tests. 
 
ADDITIONAL RISK TO THE SUBJECT: 
There is no additional risk to the subjects.  CCI
CCI
CCI
Protocol 331-201-00195  
78 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  11 References  
1 Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. Borderline personality 
disorder. Lancet. 2004;364(9432):453-461. 
2 Gask L, Evans M, Kessler D. Clinical review: personality disorder. BMJ. 
2013;347(10):f5276. 
3 National Institute of Mental Health [homepage on the Internet]. Bethesda: Borderline 
Personality Disorder. Available from: 
http://www.nimh.nih.gov/health/topics/borderline-personality-disorder/index.shtml. [Updated December 2017, Accessed 28 Aug 2018] 
4 Grant BF, Chou SP, Goldstein RB, Huang B, Stinson FS, Saha TD, et al. Prevalence, 
correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2008;69(4):533-545. 
5 Truven Marketscan Treatment Pathways; January 2016-December 2017, Otsuka Data 
on File. 
6 National C omorbidity Survey Replication. Biol Psychiatry. 2007. 
7 American Psychiatric Association. Practice Guideline for the Treatment of Patients 
with Major Depressive Disorder, Third Edition. Arlington, VA: American Psychiatric 
Association; 2010. 
8 American Psychiatric Association: Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition. Washington, DC: American Psychiatric Association, 2013. 
9 Lenzenweger MF, Lane MC, Loranger AW, Kessler RC. DSM -IV personality 
disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 
2007;62(6):553-564. 
10 Otsuka Pharmaceutical Co, Ltd., Otsuka Pharmaceutical Development & 
Commercialization, Inc., H. Lundbeck A/S. REXULTI® (brexpiprazole) Investigator's Brochure, Edition 14. Otsuka Report, issued 01 Aug 2018. 
11 Black DW, Zanarini MC, Romine A, Shaw M, Allen J, Schulz SC. Comparison of 
low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo- controlled trial. Am J Psychiatry. 
2014;171(11):1174-1182. 
12 Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, et al. A dose 
comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011;72(10):1353-1362. 
13 Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in 
patients with borderline personality disorder and comorbid dysthymia. Biol 
Psychiatry. 1999;46(10):1429-1435. 
Protocol 331-201-00195 
79 
Confidential - Proprietary Information  Amendment 1 Approval: 01 Jul 2020 14 Schulz SC, Zanarini MC, Ba teman A, Bohus M, Detke HC, Trzaskoma Q, et al. 
Olanzapine for the treatment of borderline personality disorder: variable dose 
12-week randomised double-blind placebo- controlled study. Br J Psychiatry. 
2008;193(6):485-492. 
15 Chengappa KN, Ebeling T, Ka ng JS, Levine J, Parepally H.  Clozapine reduces severe 
self-mutilation and aggression in psychotic patients with borderline personality 
disorder. J Clin Psychiatry. 1999;60(7):477-484. 
16 Belli H, Ural C, Akbudak M. Borderlin e personality disorder: bipolarity, mood 
stabilizers and atypical antipsychotics in treatment. J Clin Med Res. 
2012;4(5):301-308. 
17 Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, et al. 
Aripiprazole in the treatment of patients with borderline personality disorder: a 
double-blind, placebo-controlled study. Am  J Psychiatry. 2006;163(5):833-838. 
18 Nickel MK, Loew TH, and Pedrosa Gil, F.  Aripiprazole in treatment of borderline 
patients, part II: an 18-month follow-up. Psychopharmacology. 2007;191:1023-1026. 
19 DeBellis MD, Lefter L, Trickett PK, Putnam FW. Urinary catecholamine excretion in 
sexually abused girls. J Am Acad Child Adol Pschiatry. 1997;33(3):320-327. 
20 Friedel RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. 
Neuropsychopharmacol. 2004;29:1029-1039. 
21 Joyce PR, Stephenson J, Kennedy M, Muld er RT, McHugh PC. The presence of both 
serotonin 1A receptor (HTR1A) and dopamin e transporter (DAT1) gene variants 
increase the risk of borderline personality disorder. Frontiers in Genetics. 2014;4(313):1-7. 
22 Martin-Blanco A, Ferrer M, Soler J, A rranz MJ, Vega D, Bauza J, et al. An 
exploratory association study of the infl uence of noradrenergic genes and childhood 
trauma in borderline personality diso rder. Psychiatry Research. 2015;229:589-592. 
24 The Practical Guide: Identification, ev aluation, and treatment of overweight and 
obesity in adults. Develope d by National Institutes of He alth National Heart, Lung 
and Blood Institute. North American Asso ciation for the Study of Obesity. NIH 
Publication Number 00-4084, October 2000. 
25 Simpson GM, Angus JW. A rating scale fo r extrapyramidal side effects. Acta 
Psychiatr Scand Suppl . 1970;212(Suppl 44):S11-19. 
26 Barnes TR. A rating scale for drug-i nduced akathisia. Br J Psychiatry. 
1989;154:672-676. 
27 International Council for Harmonisation (I CH) [homepage on the Internet]. E6(R2): 
Good Clinical Practice: Integrated Ad dendum to ICH E6(R1) [finalized 2016 
November; cited 2019 Ju l 8]. Available from: 
https://www.ich.org/fileadmin/Public_Web_S ite/ICH_Products/Gui delines/Efficacy/
E6/E6_R2__Step_4_2016_1109.pdf. 
 CCI
Protocol 331-201-00195  
80 
Confidential - Proprietary Information   Amendment 1 Approval : 01 Jul 2020  Agreement  
I, the undersigned principal investigator, have read and understand the protocol (including the 
Investigator's Brochure) and agree that it contains all the ethical, legal and scientific information necessary to conduct this trial in accordance with the principles of Good Clinical Practices and as 
described herein and in the sponsor's (or designee's) Clinical Trial Agreement. 
 
I will provide copies of the protocol to all physicians, nurses, and other professional personnel to 
whom I delegate trial responsibilities. I will discuss the protocol with them to ensure that they are 
sufficiently informed regarding the investigational new drug, OPC -34712, the concurrent medications, 
the efficacy and safety parameters and the conduct of the trial in general. I am aware that this protocol must be approved by the Institutional Review Board (IRB) or receive a favorable opinion by the 
Independent Ethics Committee (IEC) responsible for such matters in the clinical trial facility where OPC -34712 will be tested prior to commencement of this trial. I agree to adhere strictly to the attached 
protocol (unless amended in the manner set forth in the sponsor's Clinical Trial Agreement, at which time I agree to adhere strictly to the protocol as amended).  
 
I understand that this IRB/IEC -approved protocol will be submitted to the appropriate regulatory 
authority/ies by the sponsor. I agree that clinical data entered in eSource by me and my staff will be utilized by the sponsor in various ways, such as for submission to governmental regulatory authorities 
and/or in combination with clinical data gathered from other research sites, whenever applicable. I agree to allow sponsor and designee monitors and auditors full access to all medical records at the 
research facility for subject s screened or enrolled in the trial. 
 I agree to await IRB/IEC approval before implementation of any substantial amendments to this 
protocol. If, however, there is an immediate hazard to subjects, I will implement the amendment immediately, and provide the information to the IRB/IEC within the required local applicable 
timelines. Administrative changes to the protocol will be transmitted to the IRB/IEC for informational 
purposes only, if required by local regulations.  
I agree to provide all subjects with informed consent forms, as required by the applicable regulations 
and by ICH guidelines. I agree to report to the sponsor any adverse experiences in accordance with the 
terms of the sponsor's Clinical Trial Agreement and the relevant regional regulation(s) and 
guideline(s). I further agree to provide all required information regarding financial certification or disclosure to the sponsor for all investigators and subinvestigators in accordance with the terms of the 
relevant regional regulation(s). I understand that participation in the protocol involves a commitment 
to publish the data from this trial in a cooperative publication before publication of efficacy and safety results on an individual basis may occur, and I consent to be acknowledged in any such cooperative 
publications that result.  
 
____________________________ _____________________________ ___________ 
Principal Investigator Print Name   Signature    Date  
 